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Trichloroethylene (TCE) induces liver cancer in mice but not in rats. Three metabolites of TCE may
contribute-chloral hydrate (CH), dichloroacetate (DCA), and trichloroacetate (TCA). CH and TCA
appear capable of only inducing liver tumors in mice, but DCA is active in rats as well. The
concentrations of TCA in blood required to induce liver cancer approach the mM range.
Concentrations of DCA in blood associated with carcinogenesis are in the sub-pM range. The
carcinogenic activity of CH is largely dependent on its conversion to TCA and/or DCA. TCA is a
peroxisome proliferator in the same dose range that induces liver cancer. Mice with targeted
disruptions of the peroxisome proliferator-activated receptor alpha (PPARa) are insensitive to the liver
cancer-inducing properties of other peroxisome proliferators. Human cells do not display the
responses associated with PPARa that are observed in rodents. This may be attributed to lower levels
of expressed PPARax in human liver. DCA treatment produces liver tumors with a different phenotype
than TCA. Its tumorigenic effects are closely associated with differential effects on cell replication
rates in tumors, normal hepatocytes, and suppression of apoptosis. Growth of DCA-induced tumors
has been shown to arrest after cessation of treatment. The DCA and TCA adequately account for the
hepatocarcinogenic responses to TCE. Low-level exposure to TCE is not likely to induce liver cancer in
humans. Higher exposures to TCE could affect sensitive populations. Sensitivity could be based on
different metabolic capacities for TCE or its metabolites or result from certain chronic diseases that
have a genetic basis. Key words: chloral hydrate, dichloroacetate, liver tumors, mode of action,
trichloroacetate, trichloroethylene. - Environ Health Perspect108(suppl 2):241-259 (2000).
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Trichloroethene (TCE) presents an interesting
problem in environmental risk assessment.
Acutely, it is much less toxic than chlorinated
hydrocarbon solvents that were developed
early (e.g., carbon tetrachloride, chloroform)
(1). The chlorinated hydrocarbons had
replaced the extremely flammable petroleum
distillates used previously for many industrial
applications. Because ofthe combination of
low acute toxicity and flammability, TCE
came into broad use as a solvent and degreas-
ing agent. This broad usage led to inappropri-
ate disposal. The high mobility ofTCE in the
subsurface and the relative ease bywhich it can
be measured at very low concentrations virtu-
ally guaranteed that it would become a pivotal
chemical in the development and application
ofrules and regulations where intent has been
to protect thepublic health (2).
The major economic reason for reexamin-
ing the risk assessment for TCE is that it is
frequently a difficult problem for compliance
with certain environmental laws, particularly
the Comprehensive Environmental Response,
Compensation, and LiabilityAct (CERCLA).
Compliance with these laws has been respon-
sible for much of the costs associated with
cleanup of uncontrolled hazardous waste
sites. The national costs for cleanup are huge,
running into the billions of dollars (3).
Therefore, relaxation ofcleanup standards
could save considerable public and private
resources. However, reevaluation of this
potential carcinogenic risk against proposed
cancer risk assessment guidelines ofthe U.S.
Environmental Protection Agency (U.S.
EPA) (4) has broader implications. The
metabolites ofTCE thought responsible for
its induction ofliver tumors are also produced
in the chlorination ofdrinking water (5). In
the case ofdrinking water disinfection, the
putative cancer risks from the formation of
these compounds need to be balanced with
the clearly established benefits ofchlorination
in the protection ofpublic health from water-
borne infectious disease (5,6).
Aside from its importance in the public
policy arena, TCE is a classic example of a
chemical that affects different target organs in
different species and strains ofexperimental
animals. This presents a challenge to risk
assessment because the risk to humans can
only be established bycareful consideration of
the mechanisms by which each cancer is pro-
duced. In some species, differing target
organs may be attributed to quantitative dif-
ferences in predominant pathways ofmetabo-
lism (7-9). Clearly, different metabolites of
TCE target different organ systems.
However, there also appear to be some intrin-
sic species differences in susceptibility to the
effects ofthese metabolites.
In general, the tumor site in each species
or strain in which TCE induces cancer corre-
sponds to those sites in which the spontaneous
frequency is greater for that strain or species.
It may be reasonably assumed that sufficient
numbers ofinitiated cells are present in such
organs and a variety of mechanisms could
accelerate the development of these sponta-
neous tumors. The contribution ofsome of
these mechanisms or modes of action to
carcinogenesis may not be linear at lowdoses.
The focus ofthis review is the induction
ofhepatic tumors by TCE. The probability
(possibility) that this response is strain spe-
cific will be considered in the context of
which metabolites are most likely to be
responsible. Second, the possibility must be
considered that the same mechanisms that
have been identified in the sensitive strain
(B6C3F, mice) provide a more general warn-
ing or alert that TCE could present a hazard
in humans for cancer. The effects ofTCE on
other target organs are considered by other
authors (8,9).
In the course of this review, four modes
ofaction are considered as they relate to the
induction of liver tumors: somatic muta-
tion, modification of cell signal pathways
(peroxisome proliferation; other mecha-
nisms that modify cell replication and death
rates), cell death and reparative hyperplasia,
and hepatomegaly/cytomegaly.
Ability ofTCE to Induce
Hepatic Cancer
TCE and several ofits metabolites have been
shown to produce hepatic cancer in experi-
mental animals. Table 1 lists carcinogenesis
bioassays in which TCE induces hepatic
cancer, followed by a listing of studies in
which liver tumor induction was evaluated
but not found. Essentially, these data show
that TCE only produces liver tumors in
selected strains of mice (B6C3F, and Swiss)
(10-12) despite adequate studies in several
strains of rats (13) and in hamsters (14). A
number of studies in other strains of mice
have also been negative for liver tumor induc-
tion even though the dosing schedule and
duration of the studies should have been
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Table 1. Evidence of livertumor induction bytrichloroethylene in experimental animals.
Route/ Duration of Duration of
Species/strain/sex method Dose treatment observation Liver tumor incidence (%) Reference
Mice/B6C3F1/M, F Oral, COG F: 869, 1,739 mg/kg 78 weeks 90 weeks F: 0, 5%; L, 52%; H, 65% (10)
M: 1,169, 2,339 mg/kg M: 0, 0%; L, 8%; H, 23%
Rats/Osborne- Oral, COG B: 549, 1,097 mg/kg 78weeks 110 weeks 0 incidence at all doses (10)
Mendel/M, F
Mice/NMRI/M, F Inhalation B: 0, 100, 500 ppm 18 months 30 months M: 0, 6.6%; 100, 6.9%; 500, 0% (14)
F: 0, 0%; 100, 0%; 500, 0%
Rats/Wistar/M, F Inhalation B: 0, 100, 500 ppm 18 months 36 months M: 0, 0%; 100, 3.3%; 500, 0% (14)
F: 0, 0%; 100, 3.3%; 500, 0%
Hamsters/Syrian/M, F Inhalation B: 0, 100, 500 ppm 18 months 30 months M: 0, 0%; 100, 0%; 500, 0% (14)
F: 0, 3.4%; 100,3.4%; 500, 0%
Mice/ICR/F Inhalation F: 50, 150, 450 ppm 104weeks 107 weeks 0, 0%; 50, 0%; 150, 0%; 450, 2% (16)
Rats/Sprague-Dawley/F Inhalation F: 50, 150, 450 ppm 104weeks 107 weeks 0, 0%; 50, 2%; 150, 0%; 450, 2% (16)
Mice/ICR-HA/M, F Oral, COG M: 2.4g/kg 18 months 106 weeks M: 0, 6%; 2.4, 10% (15)
F: 1.8 mg/kg F: 0, 0%; 1.8, 2%
Rats/ACI/M, F Oral, COG B: 500, 1,000 mg/kg 103 weeks 103 weeks M: 0, 2%; L, 2%; H, 2% (13)
F: 0, 0%; L, 0%; H, 0%
Rats/August/M, F Oral, COG B: 500, 1,000 mg/kg 103 weeks 103 weeks M: 0, 0%; L, 0%; H, 0% (13)
F: 0, 4%; L, 0%; H, 0%
Rats/Marshall/M, F Oral, COG B: 500, 1,000 mg/kg 103 weeks 103 weeks M: 0, 2%; L, 0%; H, 0% (13)
F: 0, 0%; L, 0%; H, 0%
Rats/Osborne- Oral, COG B: 500, 1,000 mg/kg 103 weeks 103 weeks M: 0, 0%; L, 0%; H, 2% (13)
Mendel/M, F F: 0, 0%; L, 0%; H, 0%
Mice/B6C3F1/M, F Oral, COG B: 1,000 mg/kg 105 weeks 105 weeks M: 0, 29%; 1,000, 78% (11)
F: 0, 13%; 1,000, 45%
Rats/F344/M, F Oral, COG B: 500, 1,000 mg/kg 103 weeks 103 weeks Notsignificant (11)
Rats/Sprague-Dawley/M, F Inhalation B: 100, 300, 600 ppm 104weeks Until death Not significant (12)
Mice/B6C3F1/M, F Inhalation B: 100, 300, 600 ppm 78 weeks Until death M: 0, 3.3%; 100, 1.1%; 300, 3.3%; 600, 6.2%a (12)
F: 0, 2.2%; 100,4.4%; 300, 4.4%; 600, 10%
Mice/B6C3F1/M, F Inhalation M: 100, 300, 600 ppm 78 weeks Until death 0, 18.9%; 100, 21.1%; 300, 30%; 600, 23.3% (12)
Mice/Swiss/M, F Inhalation B: 100, 300, 600 ppm 78weeks Until death M: 0, 4.4%; 100, 2.2%; 300, 3.3%; 600, 14.6% (12)
F: 0,0%; 100, 0%; 300, 0%; 600, 1.1%
Abbreviations: B, both sexes; COG, corn oil gavage; F,female; H, high; L, low; M, male. &Earlymortality resulted in second experiment in maleB6C3F, mice.
adequate; e.g., ICR mice (15) and male and
female ICR-HA mice (14). While TCE
induced liver tumors only in mice adminis-
tered by corn oil gavage, it produced tumors
at other sites in mice via inhalation and rats
via inhalation or gavage (12,16). It has also
been associated with small excess risks for
liver cancer and other tumor sites in epidemi-
ologicstudies (17).
The epidemiologic evidence provides
some support for the hypothesis that TCE
poses a liver cancer risk in humans; however,
this evidence is not strong. The International
Agency for Research on Cancer (IARC) (1)
recently concluded that limited evidence
existed for liver cancer but that risk was not
consistent across all studies. IARC placed
greatest weight on three studies of occupa-
tional exposure: the Spirtas et al. (18) study
ofaircraft workers and two studies ofsolvent-
exposed workers, Axelson et al. (19) and
Anttila et al. (20). When the results ofall
three studies were combined, the data appear
to indicate elevated risks for liver and biliary
tract cancer (relative risk [RR] = 1.79, 95%
confidence interval [CII: 1.13-2.68). RR was
not elevated to astatisticallysignificantdegree
in any individual study. Weiss (17) also
examined a slightly different database than
IARC (1) and drew similar conclusions.
Chiefamong the studies considered by Weiss
were the studies ofSpirtas et al. (18), Axelson
et al. (19), Anttila et al. (20), and one other
study ofthe Hughes Aircraft employees (21).
These studies indicated a total of 16 cases of
primary liver cancer (a category that excludes
cancer ofthe biliary tract) in which 9.5 were
expected. Weiss (17) cautioned that the
modest size ofthe increased risk and the lack
ofan exposure trend in the Spirtas et al. (18)
study provide limited support for a causal
hypothesis.
EvidenceofSomaticMutation
ProducedbyTCE
There have been several reviews published on
the mutagenic effects ofTCE and its metabo-
lites (22,23). An update of the literature is
included as a separate effort in this review
(24). Briefly, TCE has demonstrated a very
limited ability to induce point mutations or
clastogenic effects in a variety ofbacterial,
yeast, or mammalian cells used for in vitro
testing. Although there have been scattered
positive results, most of these results are
equivocal or have not been independently
confirmed (23). Therefore, data on the muta-
genic effects will be confined to considera-
tions ofevidence that a chemically induced
somatic mutation plays a role in the develop-
ment ofliver tumors.
The only evaluations ofgenotoxicity data
ofTCE that are directly relevant to liver
tumor induction were studies of in vivo
unscheduled DNA synthesis in rats and mice
(25-27). All three studies were negative. Less
direct assessments ofthe interaction ofTCE
with DNA have been conducted, but the
actual mechanisms involved have not been
established. For example, Walles (28) and
Nelson and Bull (29) reported that TCE was
capable of inducing single-strand breaks
(SSBs) in hepatic DNA ofboth rats and mice
in vivo. SSBs can reflect a number ofphysio-
logical responses as well as direct effects ofa
chemical on DNA.
Covalent binding ofradioactivity from
4C-TCE to DNA in vivo is very low
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(30,31). No specific adducts could be isolated
(31,32). Bergman (32) assumed that the
radioactivity associated with DNA is largely
accounted for by metabolic incorporation of
Cl fragments. A large fraction (65-90%) of
the 14C-TCE reported to bind to protein is
actually metabolically incorporated as glycine
and serine presumably via the intermediate
glyoxylate (33,34). Once in this pool, the
label can be incorporated into other amino
acids, such as alanine, thatwere not measured.
Therefore, simple association oflabel cannot
be accepted as evidence ofcovalent interaction
with TCE and any metabolites ofits oxidative
pathway (34). Glycine is also a precursor for
DNA synthesis. Caution must still be exer-
cised, as new studies that focus on incorpora-
tion oflabel using more sensitive techniques
have been performed without apparent appre-
ciation of this problem (35). While these
studies certainly overestimated the amount of
covalent binding ofTCE to protein, addi-
tional work has provided evidence ofcovalent
binding to protein bycorrection for metabolic
incorporation (34) or through the use of
immunochemical techniques (36). These data
suggest that the ability ofTCE or its oxidative
metabolites to interact with hepatic DNA
directly isverylimited.
Elevated levels ofproducts oflipid peroxi-
dation and 8-hydroxy-2-deoxyguanosine/
2-deoxyguanosine ratios have been observed
in the liver ofrats treated with TCE at a dose
of 1,000 mg/kg but not at 500 mg/kg (37).
Free radicals have also been trapped when
TCE is incubated with liver slices in vitro
(38). Consequently, there is the possibility
that radicals may contribute to the carcino-
genic response. In part, these effects could
contribute to the tumor response by increas-
ing mutation rates in the target tissues.
However, these effects become less ofa con-
cern at lower doses because of the much
higher levels ofsimilar damage produced by
the normal energy metabolism ofthe body.
Oxidative stress is also closely associated with
tumor promotion mechanisms (39). The
ability ofhepatocarcinogenesis metabolites of
TCE to contribute to such responses is dis-
cussed in later sections ofthis review dealing
with the effects ofits metabolites.
A report by Anna et al. (40) indicated
that TCE-induced tumors possessed a differ-
ent mutation spectra in codon 61 of the
H-ras oncogene than those observed in
spontaneous tumors ofcontrol mice. Results
ofthis type have been interpreted as suggest-
ing that a chemical is acting by a mutagenic
mechanism (41). As indicated in the review
ofMaronpot et al. (42), it is not possible to
a priori rule out a role for selection in this
process. However, differences in mutation
frequency and spectra in this gene provide
some insight into the relative contribution
of different metabolites to TCE-induced
liver cancer.
Anna et al. (40) and Ferreira-Gonzalez
et al. (43) independently assessed the fre-
quency of H-ras mutations and spectra in
dichloroacetate (DCA)-induced tumors.
These published data and those ofhistorical
controls for male B6C3F1 mice (40) specifi-
cally at codon-61 of H-ras are displayed in
Table 2. The mutation frequency in DCA-
induced tumors does not differ significantly
from that observed in spontaneous tumors.
However, there is an obvious change in the
mutation spectra in codon 61, involving a
significant increase in the H~ras-61CA muta-
tion at the expense ofthe H-ras-61AAA muta-
tion. The mutation spectra found in
DCA-induced tumors has a striking similar-
ity to those observed in TCE-induced
tumors and is different than those ofTCA-
induced liver tumors.
New data are becoming available that have
only been reported in abstract form (44). As
noted in Table 2, the mutation spectra of
mouseliver tumors obtainedfrom mice treated
with TCA appear to be different than those
induced with DCA (43). Only 11 TCA-
induced tumors, ofwhich 5 had detectable
mutations in codon 61 ofH-ras, were utilized
in this analysis. The new data (44) indicate a
mutation frequency in a larger number of
TCA-induced tumors (n = 30) of0.53. The
ratio ofAAA:CGA:CTA in codon 61 was
found to be 3:2:1 (44). DCA-induced tumors
were found to have a low mutation frequency
(0.33) and to have an excess ofthe CTAmuta-
tion (ratio = 6:7:7), showing the same shift
from the AAA to the CTA mutation reported
previously (42). Incontrastwith previousdata,
tumors were examined in animals that had
been treated with TCE in an aqueous vehide.
These tumors had a lower mutation frequency
than the previous data from tumors induced
by TCE in a corn oil vehicle (0.24 vs 0.51).
However, the mutations spectra were 3:2:5,
similar to those reported previously (42) for
TCE-induced tumors (ratio = 6:5:9). The
lower mutation frequency and the relative
enrichment ofthe CTA mutation with TCE
and DCA suggest a common mechanism.
Thus, DCA may play a role in the hepatocar-
cinogenicity ofTCE in mice despite its low
level of formation (discussed later). It is
notable that a mutation frequency lower than
historical controls, as seen with TCE when
administered in water rather than corn oil and
with DCA, are more consistent with the activ-
ity ofother chemicals that act as tumor pro-
moters (42). The relatively high mutation
frequencyfoundwith TCA is atypical ofother
peroxisome proliferators (42).
Difficulties in interpreting mutation spec-
tra are just coming to light. The presence or
absence of ras mutations cannot be correlated
with the extent to which ras-dependent path-
ways are expressed in the liver (45). Recently,
it was found that tumors induced by DCA in
female B6C3Fi mice had averylowfrequency
ofH-ras mutations (46). Consequently, it is
difficult to conclude that the induction of
H-ras mutations plays an initiating role for
livercancerin mice.
It is important to consider the large differ-
ences in blood levels ofDCAthat are achieved
by minimally carcinogenic doses and those
used in the experiments in which mutation
spectra were measured. As indicated above,
the concentrations ofDCA measured in the
blood ofmale B6C3F, mice drinking 0.5 g/L
were found to be 2-3 pM, whereas in mice
consuming 2 g/LofDCAconcentrations were
found to be 300 pM during the period of
active water consumption (47). Blood con-
centrations of DCA in mice gavaged with
1,000 mg/kg TCE are less than 2 pM, the
limit of quantitation in the early studies
Table 2. Mutation frequency and spectra with codon-61 of H-ras of hepatocellular adenomas and carcinomas from
B6C3F1 mice treated with TCE and its metabolites.a
Numberof Mutation
Chemical (reference) H-ras 61/tumors frequency gin CAA lys AM arg CGA leu CTA
Male mice
Spontaneous (42) 183/333 0.55 150(0.45) 106(0.32) 50(0.15) 21 (0.06)
Dichloroacetate
1 g/Lx 104 weeks (43) 6/13 0.46 7(0.54) 1(0.08) 3(0.23) 2(0.15)
3.5g/L x 104weeks(43) 16/33 0.48 17 (0.52) 3(0.09) 8(0.24) 5(0.15)
5g/L x 76 weeks (42) 40/64 0.63 24(0.37) 11 (0.17) 14(0.22) 15(0.23)
Trichloroacetate (43)
4.5g/L x 104weeks 5/11 0.45 6(0.55) 4(0.36) 1(0.09) 0(0)
Trichloroethylene (42) 39/76 0.51 37(0.49) 12(0.16) 10(0.13) 17 (0.22)
Female mice
Spontaneous (42) 33/49 0.67 16(0.33) 17 (0.35) 12(0.27) 4(0.08)
Dichloroacetate (46)
3.5 g/L x 104weeks 1/22 0.05 21(0.95) 0(0) 0 (0) 1(0.05)
'Mutations at othercodons were notincluded, although these tumors are kept as part ofthe denominator.
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(48,49). The concentrations used to obtain
mutation spectra published to date were taken
largely from animals treated with 3.5 or 5 g
DCA/L. Therefore, the effects oflower doses
ofDCA (0.14.5 g/L) are more appropriately
considered forcomparisons toTCE.
ModificationofCell-SignalingPathways
Peroxisomeproliferation. Elcombe (50)
examined the relative dose-response relation-
ships in Swiss mice andWistar-derived rats to
TCE. TCE significantly increased cyanide-
insensitive acyl coenzyme A (acyl-CoA) activ-
ity in the mice at doses ofTCE as low as 100
mg/kg per day for 10 days. The response
approached a maximum as doses approached
500 mg/kg. Although this is not the mouse
strain in which liver tumors have been
induced by TCE, at least these data show
consistent species congruence between perox-
isome proliferation and liver tumorigenesis.
TCE also induced peroxisome proliferation
in Wistar rats; however; liver tumor induc-
tion has not been identified despite studies in
several strains ofrat (10,11,13).
The importance ofchemicals that are
peroxisome proliferators as carcinogenic haz-
ards to humans is controversial. There are
data which indicate that chemicals that
induce peroxisome synthesis in rodent liver in
vivo and isolated rodent hepatocytes in vitro
fail to produce this response or are much less
potent in inducing such responses in human
hepatocytes (51). The reason for this species
difference remains to be established. Despite
a large amount ofdata that correlate peroxi-
some proliferation with carcinogenesis, the
actual mechanism by which such chemicals
actually produce cancer may be only loosely
associated with peroxisome proliferation,
per se. The most frequently cited basis is a
lower level ofexpression ofthe peroxisome
proliferator activated receptor alpha (PPARa)
(52). The quantitative relationships between
potency ofthese chemicals as rodent hepato-
carcinogens and as peroxisome proliferators
are frequentlyquite divergent.
Issemann and Green (53) isolated the
PPARa from mouse liver that activated a
response element to increase the activity ofa
reporter gene. This receptor responded to
TCA at concentrations in the mM range,
approximately the same range that would be
reached in blood ofmice by treatment with
TCE at the doses (54) employed in the NCI
and NTP bioassays. Recent experiments with
mice with a targeted disruption of the
PPARa gene abolished the pleiotropic
responses ofperoxisome proliferators. Neither
hepatomegaly, peroxisome proliferation, or
transcription activity ofthe genes that pro-
duce peroxisomal enzymes were observed in
response to clofibrate or Wy-14,643 (55).
Also, cytochrome P450s ofthe CYP4Afamily
were not induced. More important, mice
with the targeted disruption ofthe PPARa
gene were insensitive to the carcinogenic
activity ofa potent peroxisome proliferator,
Wy-14,643 (56). Mice ofthe same strain that
had an intact PPARa gene did develop
tumors. Thus, it is clear that many ofthe
responses traditionally associated with peroxi-
some proliferators are mediated through the
PPARot. However, such studies have not been
conducted with TCE or any ofits hepato-
carcinogenicmetabolites.
Despite the lack ofresponse or reduced
sensitivity ofhuman cells to the pleiotropic
responses to peroxisome proliferators, theydo
possess an analogous protein (57). Addi-
tionally, cis-acting peroxisome proliferator-
responsive elements have been identified in
the 5'-flanking region of the peroxisomal
fatty acyl-CoA oxidase gene in humans (58).
Therefore, a definitive explanation for this
differential sensitivity has yet to emerge. It
does appear that the activation ofthe receptor
is frequently indirect. In some cases it appears
that it is activated by an increase in the intra-
cellular concentrations offatty acids (59).
Another possibility lies in the fact that the
activity ofPPARa is modified by formation
ofdimers with other forms ofthe receptor
(57). This inhibitory protein has been
referred to as hNUC1 or PPARy. The lower
levels of PPARa in human liver relative to
the rodent liver may change the influence of
the two receptors.
The PPARs heterodimerize with the 9-cis-
retinoic acid receptor (RXR). The het-
erodimer is responsible for activating
transcription. The RXRIPPARa heterodimer
activates the PPAR response element (60),
but the PPARa downregulates the transcrip-
tional activity because of the thyroid hor-
mone receptor, apparently by competing for
RXR binding (61). In addition, the
PPARa/RXR heterodimer can inhibit trans-
activation by the estrogen receptor (62).
These interactions suggest that the PPARs
may play an important role in the develop-
mental biology of most species, including
humans (59).
Cytotoxicity and reparative hyperplasia.
Many chlorinated hydrocarbon solvents are
cytotoxic to hepatocytes. In a number ofcases
there are convincing data to suggest that these
effects contribute to the induction ofliver
cancer. Chloroform (63) andcarbon tetrachlo-
ride (64,65) areperhaps the bestexamples.
TCE is much less cytotoxic to the liver
than these other chlorinated solvents. Buben
and O'Flaherty (66) found liver hypertrophy
in Swiss-Cox mice at doses ofTCE as low as
100 mg/kg for 6weeks, but there was little
evidence ofnecrotic injury. There were some
increases in serum glutamate-pyruvate
transaminase levels but only at doses much
greater than required for carcinogenesis (i.e.,
2,400 and 3,200 mg/kg) and that were fre-
quently fatal as a result ofCNS depression. A
necrotic response to TCE appears to require
doses or dose rates significantly greater than
those that induce liver cancer (50,67-69).
Robust studies of the dose-response
relationships in TCE-induced modifications
of cell replication rates do not seem to be
available. Treatmentswith TCErangingfrom
single doses to repeated doses over several
weeks were seen to increase rates ofcell divi-
sion in the liver ofB6C3F, mice without
attendantsigns ofnecrosis (50,68).
Hepatomegaly/cytomegaly. Hepatomegaly
is routinely observed in mice that are treated
with hepatocarcinogenic doses of TCE.
Buben and O'Flaherty (66) noted the effect
with doses as low as 100 mg/kg per day for 6
weeks in Swiss-Cox mice. Tucker et al. (69)
found significant increases in liver size when
CD-1 mice were treated with 1, 2.5, or 5 g/L
in drinking water for 6 months. These con-
centrations in drinking water would provide
doses very similar to those used in the Buben
and O'Flaherty (66) studyusing corn oil gav-
age. In B6C3F1 mice, Dees and Travis (68)
noted significant increases in the liver-to-
body weight ratio within 10 days at 100
mg/kg and significant increases in absolute
liver weights at 250 mg/kg. Therefore,
hepatomegaly is observed at doses well below
those shown to induce hepatic tumors in
B6C3F, mice (Table 1).
Hepatomegaly can arise from increases in
cell number or cell size. In the case ofTCE,
the effect is associated with significant
decreases in the concentrations of DNA
(expressed as mg/g wetweight) (50,66). This
indicates that at least some ofthe effect is
attributable to cytomegaly and cannot be
entirelyattributed to increased cell numbers.
Metabolism ofTCE
The metabolism ofTCE is schematically
depicted in Figure 1. This is simply to identify
where those metabolites considered mostlikely
to produce hepatic tumors fit into the meta-
bolic scheme. Other reviews will more thor-
oughly address the characteristics of the
individual metabolic steps and their variation
between species (11) and the pharmacokinetics
ofTCEandcritical metabolites (70).
From the perspective of liver tumor
induction, the oxidative pathway ofTCE
metabolism appears to be the most impor-
tant. Three products ofthis pathway have
been shown capable ofinducing liver cancer
in B6C3F, mice, chloral hydrate (CH) (71),
trichloroacetate (TCA) (72-74) and DCA
(71-76). As there are also some potential
reactive intermediates in both the oxidative
and glutathione conjugation pathways, much
ofthis review will dwell on the question of
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whether the hepatocarcinogenic effects of
TCE can be accounted for by one or more of
these three metabolites. If not, perhaps other
metabolites may need to be invoked.
CH arises as a key intermediate in the
oxidative pathway (77,78), as it is produced by
rearrangement of a trichloroethylene-
oxygen-cytochrome P450 complex (79). CH
is either rapidly reduced to trichloroethanol
(TCOH) or oxidized to TCA. In most species,
TCOH is rapidly glucuronidated and the glu-
curonide is secreted into the bile. It is then
secreted into the small intestine, hydrolyzed
back to TCOH in the gut, reabsorbed and
available to either be oxidized to TCA through
CH as an intermediate, or reconjugated with
glucuronic acid (80-83). Normal humans are
proficient at glucuronidating TCOH relative
to rodents, particularly mice (9,82).
Deficiencies in the ability to glucuronidate
chemicals are, however, relatively frequent in
the human population.
The glutathione pathway of TCE does
lead to the formation ofa clearly mutagenic
metabolite, dichlorovinylcysteine (84). The
N-acetyl derivative ofthis metabolite has also
been identified in both rat (85) and human
urine (86), and it has been postulated
responsible for renal tumor induction in the
rat (85) and possibly in humans (87-89).
The metabolites within this pathway have not
been linked to liver tumor induction.
Ability of Metabolites ofTCE
to Induce Hepatic Cancer
Table 3 lists studies that have associated
hepatic tumor induction with various metabo-
lites ofTCE. These include trichloroacetalde-
hyde (CH), TCA, and DCA. It is notable that
ofthese three metabolites, only DCA has been
shown capable ofinducing hepatic tumors in
species other than the B6C3F, mouse. DCA
induces hepatic tumors in both male and
female B6C3F, mice (72-75) and male F344
rats (90,91). CH and TCA have been evalu-
ated in F344 rats under similar conditions and
did not induce hepatic tumors at similar doses
that were employed for studies in mice
(92,93).
The remainder of this review explores
what is known ofthe mechanisms and modes
ofaction ofTCE and its metabolites to iden-
tify those variables that are important to the
liver tumor response. Such an analysis is nec-
essary to determine whether TCE poses a
significant risk for liver cancer to humans
exposed to environmental levels.
Hepatocarcinogenicity of
ChioralHydrate
Chloral hydrate has been reported to produce
hepatic tumors in male B6C3F1 mice in two
studies. One study administered a single 10
mg/kg dose of CH by intragastric intubation
TCOH -glu
TCOH
Participates inenterohepatic
recirculation
TCE > CH*
TCE(OX*** DCAC***
DCVC**
TCA*
TDAA Co2
Figure 1. Simplified outline of trichloroethylene metabolism. *Hepatocarcinogenic metabolite; **metabolite pro-
posed responsible for renal tumors; ***reactive intermediates. Abbreviations: CO2, carbon dioxide; TDAA, thiodigly-
colate; DCVC, dichlorovinylcysteine; GLYC, glycolate; GLYOX, glyoxylate; MCA, monochloroacetate; MCAC,
monochloroacetyl chloride; OXAL, oxalate; TCOH-glu, trichloroethanol glucuronide; TDAA, thiodiglycolate; TCE-OX,
trichloroethylene oxide.
to mice at 15 days of age (94). This led to
statistically elevated levels of tumors between
48 and 92 weeks, but the results are based on
the appearance of three adenomas and three
carcinomas among eight animals (Table 3). In
a second study, Daniel et al. (71) administered
CH to male B6C3F1 mice for 104 weeks in
drinking water at an average dose of 166
mg/kg/day resulting in a 71% incidence of
hepatic tumors (combined adenomas and car-
cinomas). The question ofwhether CH, itself,
contributes directly to the carcinogenic effects
ofTCE is difficult to determine. Two of its
metabolites, TCA and DCA, are sufficiently
potent as hepatic carcinogens in B6C3F, mice
to account for the response to CH.
Ejfects on the liver that couldcontribute to
tumorigenesis. Genotoxic effects. IARC (1)
concluded that CH was capable ofclastogenic
activity and ofinducing aneuploidy. CH tends
to be positive as a mutagen in Salmonella
typhimurium TA100 but not in TA98 (95) or
TAI535 (96). The activity towardTA100 was
very weak in one assay (95) and substantially
greater in another (96). It was notable that
Waskell (95) recrystallized CH from alcohol 6
times before subjecting it to test, suggesting the
lower activity was associated with a higher
purity chemical. Bignami et al. (96) also per-
formed other tests that indicate that CH was
capable ofinducing point mutations. A third
group found CH to be negative in TA98,
TA100, TA1535, TA1537, andTA1538 (97),
and the purity ofthe CH was specified. Keller
and Heck (98) could find no evidence of
DNA-protein cross-links with CH treatment
ofisolated rat liver nuclei. A number oflabora-
tories have shown that CH is capable of pro-
ducing chromosomal aberrations in vitro
(22,99-102), including aneuploid cells. Thus,
chromosomal effects appear to be more consis-
tentlyobserved.
Testing of clastogenic activity of CH in
vivo has produced inconsistent results. Russo
et al. (103) demonstrated nondisjunction in
mouse spermatocytes with intraperitoneal
(i.p.) injections ranging from 80 to 400
mg/kg. On the other hand, Leuschner and
Leuschner (97) were not able to detect
increased frequency of micronuclei in bone
marrow of mice or chromosome aberrations
in rat bone marrow following CH treatment.
Cytotoxic effects and reparative hyper-
plasia. Hepatocellular necrosis was also
observed in 2 of 10 male rats treated with
concentrations of either 1,200 or 2,400 mg
chloral/L ofdrinking water administered for
90 days by Daniel et al. (104). The necrosis
observed at the high dose was more severe
than that observed at the low dose, providing
some indication of a dose response. Neither
dose produced any sign ofhepatomegaly in
the rat. If it is assumed that rats drink water
to 10% of their body weight in a day, the
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Table 3. Evidence of hepatocarcinogenic effects of metabolites oftrichloroethylene in experimental animals.
Combined hyperplastic nodule and
hepatocellular adenoma Hepatocellular carcinoma
Duration Tumor/n Tumor/n
Species (sex) Dose (weeks) Tumor site Incidence (multiplicity) Incidence (multiplicity) Reference
Trichloroacetate
Mice
B6C3F1 (M)
B6C3F1 (M)
B6C3F1 (M)
B6C3F1 (F)
Rats
F344(M)
Mice
B6C3F1 (M)
B6C3F1 (M)
B6C3F, (M)
B6C3F, (F)
B6C3F, (M)
Rats
F344(M)
0
5g/L
0
1 g/L
2 g/L
2 g/L
0
0.05 g/L
0.5g/L
4.5 g/L
5g/L
0
0.35
1.2
3.5
0
0.35
1.2
3.5
0
0.05 g/l
0.5 g/L
5g/L
61
61
52
52
52
37
60-95
60
60
95
60
52
52
52
52
81
81
81
81
104
104
104
104
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
2/22
8/22
1/35
5/11
15/24
2/11
NR
NR
NR
NR
NR
1/40
6/40
3/19
2/20
2/90
14/53
12/27
18/18
2/23
2/24
5/20
1/22
0.09
0.5
0.03
0.45
1.04
0.18
NR
NR
NR
NR
NR
0.03
0.15
0.16
0.10
0.02
0.
0.
1.0
0.087
0.083
0.25
0.045
0/22
7/22
0/35
2/11
4/24
3/11
6.7-10%
22%
38%
87%
55%
0/40
0/40
0/19
5/20
2/90
0/53
5/27
5/18
0/23
0/24
0/20
1/22
0
0.5
0
0.18
0.17
0.27
0.07-0.15
0.31
0.55
2.2
0.97
0
0
0
0.25
0.02
0
0.
0.28
0
0
0
0.045
(72)
(73)
(75)
(74)
(92)
Dichloroacetate
0
5 g/L
1 g/L
2 g/L
2 g/L
0
0.5 g/L
3.5 g/L
5 g/L
0
0.05g/L
0.5 g/L
0
0.5 g/L
0
0.28
0.93
2.8
0
0.28
0.93
2.8
0
0.05
0.5
1
2
3.5
0
0.05 g/L
0.5 g/L
2.4 g/L
0
0.05
0.5
2.4
61
61
52
52
37
60
60
60
60
75
75
75
104
104
52
52
52
52
81
81
81
81
100
100
100
100
100
100
60
60
60
60
104
104
104
104
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
Liver
25/26
2/11
23/24
7/11
0/10
12/12
27/30
2/28
4/29
3/27
1/20
12/24
1/40
0/40
3/20
7/20
2/90
3/50
7/28
16/19
14/50
11/33
11/24
23/32
13/14
8/8
0/7
0/7
0/7
26/27
1/23
0/26
9/29
Not done
4.6
0.3
3.6
2.2
0
2.3
2.3
0.07
0.31
0.11
0.05
0.5
0.03
0
0.20
0.45
0.02
0.06
0.32
5.6
0.25
0.5
0.32
0.8
0.85
0.64
0
0
0
0.96
0.04
0
0.31
Not done
21/26
NR
5/24
0/11
0/10
8/12
25/30
2/20
15/24
0/40
0/40
0/20
1/20
2/90
0/50
1/28
5/19
5/50
NR
5/24
16/32
6/14
4/8
0/7
0/7
0/7
1/27
0/23
0/26
3/29
Not done
1.7
NR
0.25
0
0
1.7
2.2
0.1
0.63
0
0
0
0.1
0.02
0
0.04
0.37
0.28
NR
0.68
1.29
2.47
2.9
0
0
0
0.04
0
0
0.1
Notdone
(72)
(73)
(76)
(71)
(74)
(76)
(91)
(continued)
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Table 3. Continued.
Combined hyperplastic nodule and
hepatocellular adenoma Hepatocellular carcinoma
Duration Tumor/n Tumor/n
Species (sex) Dose (weeks) Tumor site Incidence (multiplicity) Incidence (multiplicity) Reference
Chloral hydrate
Mice
C57BLXC3HF, 0 92 Liver 0/19 0 2/19 0.11 (94)
(single dose to 5 mg/kg 2/9 0.22 1/9 0.11
neonatal mice) 10 mg/kg 3/8 0.38 3/8 0.38
B6C3F1 0 104 Liver 1/20 0.05 2/20 0.10 (71)
1 8/24 0.33 11/24 0.46
NR, not reported.
no-effect level of 1,200 mg/L corresponds to
approximately 120 mg/kg per day. This
would amount to about 18 g per day in an
adult human, close to the estimated doses in
the study by van Heijst et al. (105) discussed
more fullybelow.
In contrast to findings in rats, both CD-1
and B6C3F1 mice display hepatomegaly with
high doses ofCH. Doses of 144 mg/kg were
administered by gavage for a period of 14
days (106). No effect was observed at 14.4
mg/kg. Longer term exposures of up to 104
weeks produced similar effects at 166 mg/kg
(71). Parallel data on pathology and serum
enzyme levels indicate that CH was mini-
mally cytotoxic at these doses in mice.
Therefore, the apparent greater sensitivity of
mice (albeit ofanother strain) to the hepato-
carcinogenic effects ofCH than rats appears
to parallel the sensitivity for cytomegaly.
Clearly, the liver-enlarging effects ofCH are
observed in the same dose range (166 mg/kg)
at which tumors were induced (71). Neither
the effects nor the dose required to produce
these effects appears consistent with a contri-
bution of CH to liver tumor induction by
TCE that is independent ofthe contributions
ofsubsequent metabolites (DCAandTCA).
Hepatocarcinogenicity of
Tnichloroacetate
Trichloroacetate induces hepatocellular carci-
nomas when administered in drinking water
to male and female B6C3F1 mice (72-74).
In these studies, dose-related increases in the
incidence of malignant tumors and precan-
cerous lesions have been obtained at concen-
trations in water ofbetween 1 and 5 g/L with
as little as 12 months of treatment
(73,74,92). Significant increases in benign
lesions were observed at concentrations as low
as 0.35 g/L ofdrinking water. Under similar
conditions of treatment, TCA has not
induced hepatic tumors in F344 rats (93).
Effects on the liver that couldcontribute
to tumorigenesis. Genotoxic effects. Early
reports indicated that TCA induced SSBs in
the hepatic DNA ofmice and rats (28,107).
Subsequent experiments using the same
methodology (108) failed to replicate the
increase in SSBs observed in mice, using a
single, high 500 mg/kg dose. Using slightly
different methodology, Chang et al. (109)
found a very small but statistically significant
increase in SSBs with a dose of 1,600 mg/kg
TCA to mice but no effect at 800 mg/kg.
More recent data indicate that an oral
dose of300 mg/kg TCA has been shown to
increase oxidative damage to DNA, as mea-
sured by increased content of 8-hydroxy-2-
deoxyguanosine (8-OH-dG) content of
nuclear DNA ofthe liver when administered
in acute doses (110). However, this response
was small and not observed when male
B6C3F1 mice were treated with 2 g TCA/L
in drinking water for 3 or 10 weeks (111).
Nevertheless, lipofuscin deposits are promi-
nent in the liver ofchronically treated mice,
demonstrating some ongoing oxidative stress
in response to TCA (73). Lipofuscin is, how-
ever, absent from TCA-induced tumors.
The totality ofthe data that are available
suggests thatTCA is unlikely to damage DNA
directly, although there may be some damage
that is induced by indirect mechanisms at very
high doses. It is important to recognize that
oxidative damage to DNA is rapidly repaired
(112). Therefore, the small changes in the
background levels of8-OH-dG in DNA pro-
duced at very high doses may play little, if
any, role in TCA's contribution to thehepato-
carcinogenic responses to TCE.
Bull et al. (73) found that suspension of
treatment at 37 weeks resulted in a smaller
number oftotal tumors in mice at 52 weeks
than in mice that had been treated continu-
ously for the entire 52 weeks based upon total
dose administered. These data suggest that
benign lesions induced byTCA regressed when
treatment was suspended at 37 weeks and sup-
port the hypothesis that TCA is not genotoxic.
However, most ofthe tumors that remained in
the group in which treatment was suspended
were hepatocellular carcinomas (3 of5). This
was in contrast to the fact that only 4 of 16
tumors were found to be hepatocellular carci-
nomas in micekepton continuous treatment.
The initiation-promotion study ofPereira
and Phelps (113) also included a suspended
treatment segment. These experiments were
conducted in female rather than in male
B6C3F1 mice. TCA increased the yield of
both hepatocellular adenomas and carcinomas
in methylnitrosourea (MNU)-initiated mice
(Figure 2). TCA significantly increased the
yield ofhepatocellular carcinoma as well as
hepatocellular adenomas after 362 days of
treatment. The mice whose treatments were
suspended at 37 weeks had significantly
reduced numbers and incidences ofhepato-
cellular carcinomas at 52 weeks relative to ini-
tiated mice treated for the full 52 weeks with
TCA. The hepatocellular carcinoma yield
within the group that had its treatment sus-
pended was very close to what would have
been expected from adding the incidence of
the MNU-only and TCA-only treatment
groups. In the initiated mice, the incidence of
hepatocellular adenomas was increased to
essentially the same multiplicity whether at 31
weeks, 52 weeks, or in animals whose treat-
ments were suspended at 31 weeks and who
were sacrificed at 52 weeks. Hepatocellular
adenomas were very few in mice treated with
TCA alone. While hepatocellular adenomas
- - Cont-HA -V - Cont-HC
o -0 --- MNU-HA -v- MNU-HC
E
4
CO
CO T
E 1
4i -~~~~~~~~~~~~.
CO
[TCAJ, g/L
Figure 2. The ability of TCA to promote the formation of
liver tumors in B6C3F1 mice that have been previously
exposed to MNU as an initiator. The vertical bars indi-
cate SEM. Adapted from Periera and Phelps (113).
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were at a higher incidence and multiplicity
with TCA than with MNU alone, they
appeared remarkably insensitive to any
change in the treatment period for TCA.
There is aconsistencywith the observations of
Bull et al. (73) that suggests that the hepato-
cellular carcinomas arise from the similar cell
populations with TCA treatment in both the
whole carcinogenesis and the initiation-
promotion study.
Another publication (114) reports that
27% ofTCA-promoted tumors derived from
the B6C3F1 hybrid mice from the Pereira
and Phelps (113) studylost heterozygosity on
chromosome 6. There was no loss ofhet-
erozygosity in this chromosome in DCA-pro-
moted tumors, indicating that the effect was
not attributable to the initiator. As a conse-
quence, these data imply that either the initi-
ated cells promoted byTCA to hepatocellular
carcinomas are susceptible to this clastogenic
result spontaneously (something that is
known to happen both clinically and experi-
mentally) or that TCA could be acting as a
tumor progressor. The very weak activity of
TCA to act as a clastogen provides some basis
for the formerhypothesis (115).
Modification ofcell-signaling pathways.
TCA induces peroxisome proliferation in male
B6C3F1 mice over the same dose range that it
induces hepatic tumors (76). Unlike the situa-
tion with DCA, discussed in the next section,
increased expression ofperoxisomes by TCA
appears to be sustained over time. TCA also
induces peroxisome synthesis in F344/N rats,
but the increases in acyl-CoA oxidase activity
were only 2-3 times the control levels at the
concentrations administered in the drinking
water (93,116). This compares to a 10-fold
increase in this peroxisome markerwith similar
dosing schedule in mice. It is rare that such a
small effect on peroxisome proliferation would
betied to carcinogenesis.
It is notable that Elcombe (50) found
that the Wistar rat was actually more sensitive
than mice to increases in cyanide-insensitive
acyl-CoA oxidase activity induced by TCA.
Obviously, this is inconsistent with the rela-
tive sensitivity of these two species to the
tumorigenic effects ofTCA in that rats (in
this case F344) appear to be less sensitive than
mice (B6C3F1) (116). These results may
reflect a strain difference or they may be
attributed in part to the weak peroxisome
proliferative activity ofcorn oil, which was
thevehicle used byElcombe (50).
Modifications in rates ofhepatocyte
replication and death. The available data
suggest that TCA has tumor-promoting activ-
ity. Stauber and Bull (117) induced tumors
with TCA at 2 g/L for 50 weeks. In Figure 3,
the replication rates ofTCA-induced tumors
are shown. The rateswithin tumors from mice
in which TCA administration had been
suspended for 2 weeks still have a very high
labeling index, matching those rates observed
in tumors ofmice with continuous treatment.
Thus, there was no indication that the replica-
tion rates within tumors were modified by
TCA treatment. In contrast, TCA treatment
sharply depressed replication rates in normal
hepatocytes in the same mice in which the
long-term treatmentwas maintained until sac-
rifice. Thus, these results appear to be consis-
tent with the negative selection hypothesis
that has been advanced to explain the activity
of other tumor promoters (118). This
hypothesis suggests that cells resistant to
downregulation of mitogenic effects of a
chemical have a growth advantage over
normal cells in an organ.
Recently, TCA has been shown to stimu-
late the growth ofcolonies ofcells obtained
from the liver ofB6C3F1 mice to grow in soft
agar (119). These colonies express the c-Jun
phenotype characteristic ofTCA-induced
tumors. This is in contrast to the c-Jun+ phe-
notype observed with DCA-induced liver
tumors in mice (discussed more fully below).
These data provide strong evidence that TCA
is acting primarily by increasing the clonal
expansion ofa specific group ofinitiated cells
within the liverofthe B6C3F1 mouse.
Hepatomegaly/cytomegaly. As with other
peroxisome proliferators, treatmentwith TCA
is associated with increases in liver weight.
Increases in liver weight appeared to be more
or less linearwith dose with exposures as short
as 14 days to as much as 90 days (120,121).
These effects have been consistently observed
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at doses ofTCA as low as 0.3 g/L or approxi-
mately 100 mg/kg perday in B6C3F1 mice.
Hepatocarcinogenicity of
Dichloroacetate
Dichloroacetate is an effective inducer of
hepatic tumors in both mice and rats. Several
studies inmale andfemale B6C3F1 micefound
multiple tumors per animal with treatment
concentrations of2 g/L and abovewith as little
as 40 weeks oftreatment (71-75,117). These
studies are summarized in Table 3. At 12
months oftreatment the dose response is very
steep, with essentially no response observed at
concentrations of 1 g/L but as many as 4
tumors/liver in mice treated with 2 g/L (73).
However, concentrations as low as 0.5 g/Lwill
result in a hepatic tumor incidence ofapproxi-
mately80% in afull2-yearstudy(76).
Hepatic tumors are also induced by DCA
in male F344 rats (90,91). High doses ofDCA
given to rats produced a peripheral neuropathy
(122,123) that complicated the conduct of
cancer bioassays. Nevertheless, increased inci-
dence ofhyperplastic nodules and hepato-
cellularadenomasandcarcinomaswas observed
at 60 weeks oftreatment at 2.4 g/L (Table 3).
As in mice, ifDCA treatment was extended to
104 weeks, the incidence ofthese lesions was
41% in a group of29 rats at a treatment con-
centration of 0.5 g/L. No tumors were
observed at 0.05 g/L and only one hepatic
tumorwas observed in 33 control rats.
Effects on the liver that couldcontribute
to tumorigenesis. Genotoxic effects. The abil-
ity ofDCA to induce damage to DNA that
Tumors &Altered Hepatic Foci
70
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Figure 3. Effect of TCA on replication rates in normal hepatocytes and within tumors and altered hepatic foci. Male
B6C3F1 mice were treated with 2 g TCA/L of drinking water for 50 weeks. Atthat time they were transferred to drink-
ing water containing the concentrations indicated on the x-axis for two additional weeks. Miniosmotic pumps were
implanted to deliver BrdU for 5 days. Replication rates were measured by counting cells positive to an anti-BrdU anti-
body relative to total numbers of cells. Rates of replication in animals that were initially treated with TCA and trans-
ferred to distilled water for 2 weeks are denoted by TCA 0/g/L with dotted lines indicating the SEM. The solid line
labeled control indicates replication rates in the liver of mice carried as controls throughout the whole experiment,
with the SEM indicated by the dashed lines. Each point is labeled with the number of animals or lesions scored ±
SEM. Data from Stauberand Bull (117).
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could give rise to mutations or chromosomal
damage has received study both in vivo and
in vitro. Classical evaluations of DCA in
Salmonella tester strains, both with and with-
out metabolic activation, have been largely
negative ifheld to the standard ofat least a
2-fold increase in apparent mutation fre-
quency to identify a compound positive
(95,124). However, a number ofmore recent
studies have suggested some potential for
DCA-induced modifications in DNA.
In vitro or bacterial systems. DeMarini
et al. (125) reported that DCA induced
prophage in E. coli at concentrations of0.26
mM and produced 2.7 and4.2 revertants/ppm
in Salmonella TA100 with and without S9
addition, respectively. There are some difficul-
ties in interpreting this report, as the author
introduced DCA as a vapor and it is not clear
whether the concentrations reported (i.e.,
ppm) refer to air or media concentrations.
Also, at least in the case ofthe Salmonella
assay, the DCAwas introduced as the free acid
and allowed to vaporize and partition into the
incubation media. DCA is a strongacid with a
PKa = 1.3 (126). If DCA is adequately
volatilized and sufficient time is allowed to
come to equilibration, ion trapping would
result in near quantitative transfer ofDCA to
themedia, which in this casewouldbeapprox-
imately 0.06-0.6 M. Brusick (127) has docu-
mented genotoxic effects that are induced by
lowpH. The amount ofDCAintroduced into
the prophage assay is unclear because the
method of addition was not described,
although the introduction implied that it was
again beingtested as avolatilesubstance.
Giller et al. (128) examined a series of
haloacetic acids, including DCA, in the SOS
chromotest, the Ames' fluctuation assay, and
the newt micronucleus assay. DCA was
reported mutagenic in the Ames' fluctuation
assay, at concentrations > 100 pg/mL in the
absence ofrat liver S9 fraction and > 1,000
ig/mL in the presence ofS9. There was also a
positive response with the SOS chromotest at
500 pg/mL. The newt micronucleus assay
was negative. It appears that the free acid was
also used in these studies, as there was no
indication that the acids were neutralized.
Therefore, the value ofthese data is limited
because ofthepotential ofpH artifacts (127).
The mutagenic activity ofsodium DCA
was explored in a variety oftest systems by
Fox et al. (129). These investigations found
no evidence ofincreased mutation rates in
Salmonella tester strains TA98, TA100,
TAI535, or TAI537; E. colistrain WP2urvA;
or the mouse lymphoma forward mutation
assay whether incubated in the presence or
absence ofrat liver S9 fraction for metabolic
activation. These authors found no evidence
that DCA was capable of inducing chromo-
somal aberrations in Chinese hamster ovary
cells in vitro at doses up to 1,100 mg/kg for 3
days. These studies used neutralized DCA,
supporting the contention that positive
results in prior studies may have resulted
from artifacts secondary to the testing ofthe
free acid or because different sources ofDCA
mayhave greateramounts ofimpurities.
More convincing evidence ofmutagenic
effects ofDCA was obtained by Harrington-
Brock et al. (115) in mouse lymphoma cells.
DCA was found to increase the thymidylate
synthetase mutant frequency in a concentra-
tion range of 100-800 pg/mL. Cytogenetic
analyses documented an increased frequency
of chromosomal aberrations at 600 and
800 pg/mL.
The concentrations at which these geno-
toxic effects occur are important in determin-
ingwhether theyplaya role in either DCA- or
TCE-induced liver cancer. The lowest dose of
DCA that has been shown to produce an
increased incidence ofcancer is 0.5 g/L (71).
A concentration of0.05 g/L was found inef-
fective (76). The peakconcentrations ofDCA
that are observed with the 0.5-g/L treatment
are approximately 2-3 pM [approximately
25-40 pg/mL (45)]. Concentrations ofDCA
in the blood produced from the metabolism
ofhigh doses ofTCE (1 g/kg) in mice fall
belowthelimitofquantitation (48,49). Using
these data and assuming the project down lin-
earlywith aphysiologically basedpharmacoki-
netic model, Barton et al. (49) estimated the
area under the blood concentration time curve
(AUC) of DCA obtained from 1,000 and
2,000 mg/kg TCE doses used in the cancer
bioassays was 0.25 and 0.31 mg-hr/L. These
values fall between the estimated AUCs in
mice treated with 0.05 and 0.5 g/L in their
drinking water (0.041 and 0.72 mg-hr/L,
respectively). Available data suggest that less
DCA is formed in the metabolism ofTCE by
rats andhumans (70).
In vivo experiments. DCA was reported
to induce SSBs in hepatic DNAwhen admin-
istered by gavage to both mice and rats
(28,107). Subsequent investigators were
unable to repeat these results (92,109). A
small transitory increase in SSBs was observed
with doses of 5 and 10 gmol/kg in male
B6C3F1 mice by Chang et al. (109). More
recently, Austin et al. (110) have shown that
acute doses ofDCA produce oxidative dam-
age to nudear DNA, measured as 8-OH-dG.
The time course ofthis damage is more con-
sistent with the development ofSSBs reported
by Chang et al. (109) and could represent the
repair processes that involve strand scission.
There are two important points that must be
made: a) the induction ofSSBs by Chang et
al. (109) was very small relative to that seen
with the positive controls, diethylnitrosamine
and methylmethane sulfonate; and b)
although increased 8-OH-dG was observed
with acute treatments with DCA, there was
not a sustained elevation of this adduct in
nuclear DNA ofmice when treatments with
carcinogenic concentrations in drinking water
were carriedout for3-10weeks (111).
Fuscoe et al. (130) reported results
obtained with the mouse peripheral blood
erythrocyte micronucleus assay. They found
a small but statistically significant increase in
polychromatic erythrocytes containing
micronuclei in male B6C3Fi mice treated
for 9 days with 3.5 g DCA/L of drinking
water. This effect was not maintained
through 28 days ofexposure. These investi-
gators also examined DNA migration in the
single-cell gel assay. In this case, DCA
appeared to retard migration of DNA, sug-
gesting the possibility of DNA cross-linking
(as opposed to SSBs) after 28 days of treat-
ment at 3.5 g/L. Neither assay revealed sig-
nificant effects ofDCA at concentrations of
DCA of 2 g/L or below. It is important to
recognize that DCA induces 3 to 4 tumors
per animal within 1 year at 2 g/L in drink-
ing water (73). The higher dose adds little
to the tumorigenic response. Moreover, the
hepatic tumor incidence at 0.5 g/L is > 80%
incidence, as observed in lifetime exposures
to levels of DCA as low as 0.5 g/L (76).
This would suggest that this evidence of
potential genotoxic effects at high doses may
have little to do with the induction of
hepatic cancer by DCA.
Leavitt et al. (131) reported increased
recovery ofmutant cells from the lad trans-
genic mouse with varying periods oftreat-
ment with DCA in drinking water.
Significant increases were observed onlywhen
mice had been treated with 3.5 g/L for 60
weeks, not at shorter time intervals. No sig-
nificant increases were noted at 1 g/L. While
the authors took care to ensure that nodules
and tumors were excluded from the sampling,
Stauber and Bull (117) found that there are
numerous lesions that were smaller than nod-
ules in B6C3Fi mice maintained on 2 g/L
dichloroacetate for only 40 weeks. It was
inevitable that some of these microscopic
lesions were included within the tissue sam-
ples described. Given the marked stimulation
ofcell replication that occurs within lesions in
mice, it is probable that the effect reported by
Leavitt et al. (131) was due to the ability of
DCA to selectively stimulate the growth of
tumor precursor lesions.
Modification ofcell-signaling pathways.
Like TCA, DCA is a weak peroxisome prolif-
erator in mice (116). However, this response
is not stable, generally disappearing after a
fewweeks treatment. There is also a dear dif-
ferentiation between the lowest dose that
induces tumors, 0.5 g/L (76), and the lowest
dose that produces sustained peroxisome
proliferation, 3.5 g/L (76).
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DCA has a considerable history as a
hypoglycemic agent (132). In part, this is
probably due to the established effects of
DCA ofinhibiting the pyruvate dehydroge-
nase kinase (133). More recent data have
shown that administration ofDCA substan-
tially lowers serum insulin concentrations in
mice treated with 0.5 or 2 g/L ofDCA for 2
or more weeks (134) without significantly
affecting plasma glucose concentrations (47).
Serum insulin concentrations appear actually
to be increased in mice treated with low i.p.
doses ofDCA (. 10 mg/kg) presented with a
glucose challenge (47). Consequently, this
effect is not due to inhibition ofinsulin secre-
tion. The blood concentrations that are effec-
tive in reducing serum insulin concentrations
are in the range of 1-2 gM. The apparent Ki
of DCA for the pyruvate dehydrogenase
kinase is 200 pM (133), a concentration that
can be achieved in blood ofmice with 2 g/L
in the drinking water (47). Consequently, it
is unlikely that these two effects are produced
bythe same mechanism.
DCA increases the deposition ofglycogen
in the liver. The dose response for glycogen
deposition in the liver is in the same range
that is required for inducing hepatocarcino-
genesis (47). The accumulation ofglycogen
with DCA treatment takes a pathological
character, becoming resistant to mobilization
by fasting after 8 weeks of treatment.
Increased hepatic glycogen is capable of
inhibiting glycogen synthase, an effect that is
observed in the liver of DCA-treated mice
(47). However, DCA does not inhibit glyco-
gen synthase when incubated with liver
homogenates in vitro. The correlation of
doses raises the possibility that the accumu-
lation ofglycogen and induction of tumors
by DCA could be produced by modification
ofthe same cell-signaling pathways.
Overexpression ofthe insulin receptor 1
substrate in human liver cells is known to be a
suppressor oftransforming growth factor PI
(TGF-pl)-induced apoptosis (135). Since the
tumors express elevated amounts ofthe insulin
receptor relative to the surrounding tissue
(134), increased sensitivity to insulin could
contribute to liver tumorigenesis by DCA.
Insulin receptor expression in the normal por-
tions of the liver is sharply suppressed by
DCA, an effect that is reversed by the suspen-
sion of treatment. Presumably, this would
mean that DCA-induced tumors may be more
resistant to TGF-1i-induced apoptosis. Since
DCA-induced tumors are uniformly glycogen
poor, the accumulation ofglycogen in normal
hepatocytes could contribute to the differential
effects ofDCA treatment on insulin receptor
expression in normal hepatocytes and tumors.
Thus, it is possible that greater sensitivity of
tumor cells to insulin than normal cells could
contribute to liver tumorinduction.
Modifications in the rates ofhepatocyte
replication and death. DCA appeared to
specifically stimulate outgrowth ofhepato-
cellular adenomas rather than carcinomas.
Pereira and Phelps (113) examined the effects
of DCA as a promoter of MNU-initiated
hepatic tumors in male B6C3F, mice. These
data are provided in graphic form in Figure 4.
At a concentration of 2.6 g/L ofdrinking
water, DCA induced a large increase in the
number ofhepatocellular adenomas but had
no significant effect on the induction of
hepatocellular carcinomas.
The data of Pereira and Phelps (113)
appear to be at least partially consistent with
the stop experiments ofBull et al. (73). The
latter authors found that suspending the
treatment of male B6C3F, mice with DCA
at 37 weeks appeared to arrest progression of
liver tumors but resulted in a yield ofhepa-
tocellular adenomas and nodules that were
proportional to the total dose of DCA
administered. The initiation-promotion
experiments of Pereira and Phelps (113)
included a suspension of treatment with
DCA at 31 weeks. This resulted in a sub-
stantial decrease in the numbers of MNU-
initiated hepatocellular adenomas in female
B6C3Fi mice at 52 weeks, with little
effect on hepatocellular carcinoma yields.
Nevertheless, there is an inconsistency with
prior data. Bull et al. (73) found that the
number of DCA-induced lesions were pro-
portional to the total dose administered to
the animal whether treatment was termi-
nated at 37 or 52 weeks. The total number
of lesions seen in the Pereira and Phelps
(113) study was significantly less than would
be predicted. It is probable that the differ-
ences between the two studies are related to
the use of female rather than male mice
and/or a tumor initiator in the latter study.
It is notable, however, that the total lesion
numbers (foci + adenomas + carcinomas)
observed by Pereira and Phelps (113) were
not different depending upon whether the
MNU-initiated animals were treated with
DCA and sacrificed at 31 vs 52 weeks. The
essential difference was that more lesions fell
into the adenoma class at the expense ofthe
foci class oflesions at 52 weeks. This suggests
that DCA treatment acted to increase the rate
at which lesions develop rather than increas-
ing the number oflesions. The analysis of
Pereira and Phelps (113) did not include
measures oflesion size, but it is suggested that
progression without increases in number is
simplya function ofclonal size.
More recent studies of the effects of
DCA on cell replication within normal
hepatocytes and altered hepatic foci (AHF)
and tumors (predominately adenomas) indi-
cate that it does have selective effects.
Stauber and Bull (117) found that DCA
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Figure 4. The ability of DCA to promote the formation of liver
tumors in female B6C3F, mice that have been previously treated
with a single dose of MNU as an initiator. The vertical bars indi-
cate the SEM. Data adapted from Periera and Phelps( 113).
had a small, stimulatory effect on the repli-
cation rate of normal hepatocytes over the
first 14 days of treatment. As treatment was
extended to 28 days and beyond, these
effects became inhibitory at concentrations
in drinking water of0.5 g/L and above. In
contrast, hepatocytes within nodules and
tumors appeared to be resistant to the
inhibitory effects ofchronically administered
DCA. At a concentration of 2 g/L, DCA
doubled the rate at which cells that were
immunoreactive to c-Jun and c-Fos antibod-
ies replicated within hyperplastic nodules
and adenomas (Figure 5). This strong stimu-
lation of tumor cell replication appears to be
responsible for the very rapid induction of
tumors in mice treated with DCA in drink-
ing water at concentrations of 2 g/L and
above. It appears that the slower induction
of liver tumors at lower doses of DCA
depends primarily on the selective suppres-
sion ofthe replication ofnormal hepatocytes
relative to initiated cells.
The work of Pereira (121) confirms the
transient increase in the replication rates of
hepatocytes observed with treatment with
DCA. At 5 days of treatment there was a
dose-related increase in the rate ofreplication
at concentrations of260-2,600 mg/L. No
statistical analyses of these data were pro-
vided, but visual inspection ofthe mean val-
ues and estimates oftheir variability suggests
that statistical significance might be
approached at concentrations of 830 mg/L
and above. This response was attenuated at
12 days of treatment and appears to be
completely gonewithin 33 days oftreatment.
Carter et al. (136) also observed the
inhibitory effect of DCA on replication of
normal hepatocytes. The rate ofreplication is
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sharply inhibited within 5 days at DCA
concentrations of5 gIL. At 0.5 g/L the replica-
tion rate appeared to be inhibited to the same
extent observed with 5 g/L after 20 days of
treatment. These decreases in replication were
accompanied by decreases in the percent of
mononucleated cells, which Carter et al. indi-
cate is probably associated with an increase in
tetraploid cells. Therefore, while different
experimental designs make itdifficult to rectify
the results, it appears that dosing levels of
DCAof2.6 g/Land belowproduce atransient
increase in the replication rates ofnormal
hepatocytes. Depressed rates ofnormal hepato-
cyte replication in DCA-treated mice relative
to control animals as the treatment period
becomes more prolonged appear to be a
consistent observation across laboratory.
The suppression of cell replication in
normal hepatocytes of mice by DCA-
treatment is accompanied by decreased
apoptosis in normal hepatocytes (137). At
concentrations of 5 g/L the frequency at
which apoptotic cells are observed drops
60-75% with as little as 5 days of treat-
ment. At 0.5 g/L, there is a downward trend
that is observed over the period from 5 to
30 days such that the frequency of apop-
totic bodies at this low dose approaches that
observed at the highest dose at 30 days. This
result essentially parallels that described
above for suppression of the rates of cell
replication. This raises a question as to
whether the driver of the response is sup-
pressed replication or suppressed apoptosis.
Whichever is the case, this translates into
suppressed turnover ofnormal hepatocytes.
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The question is whether this suppressive
effect on cell turnover increases the proba-
bility of transformation of hepatocytes or
clonal expansion ofdamaged hepatocytes that
would normallybe eliminated.
Stauber et al. (119) determined the extent
to which DCA could selectively stimulate the
growth of clones ofcells derived from the
liver of naive B6C3F1 mice on soft agar.
Figure 6 indicates the time-dose-response
relationships that result when the only treat-
ment ofcells is the indicated concentrations
within the Petri dish. DCA substantially
increased the numbers ofcolonies over those
that would grow out spontaneously. A most
promising aspect of this result is that the
colonies that grew out with DCA faithfully
reproduced the phenotype (c-Jun+) of the
tumors that were produced in vivo. The
opposite phenotype was produced in TCA-
induced tumors and in clones ofcells derived
from mouse liver thatwere grown in the pres-
ence ofTCA on soft agar. A second experi-
ment was conducted where male B6C3F1
mice were treated with a minimally carcino-
genic concentration of DCA in drinking
water for 14 days and the in vitro segment of
the experiment repeated. This experiment
was predicated on the notion that ifthe main
effect ofDCA is to produce clonal expansion,
then the number of cells isolated should
increase with in vivo treatment. This occurred
as predicted. However, it was also noted that
the sensitivity of the cells obtained from
treated animals to DCA in the soft agar had
substantially increased. Figure 7 compares the
dose-response curves for naive animals and
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animals that had been pretreated. Statistically
significant increases in the numbers of
colonies were observed at the lowest concen-
tration studied, 20 1M. There was no statisti-
cally significant effect on the number of
colonies produced from plating a standard
number ofhepatocytes from naive mice until
the dosewas increased above 200 1sM.
Miller and co-workers (138) directly
examined the effect of DCA treatment on
liver tumor growth rates in mice in vivo
using magnetic resonance imaging. DCA
was administered to mice until small tumors
became apparent (-1 mm in diameter). The
animals with tumors were randomly
assigned to two groups, one in which treat-
ment was maintained and the other in
which treatment was suspended, and the
tumors imaged over the next 2-3 weeks.
The results ofthis study are shown in Figure
8. Cessation of DCA treatment essentially
abolished the growth oftumors. These data
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Figure 6. The time-course of colony formation when a
hepatocyte suspension from naive male B6C3F, mice is
plated on soft agar with the indicated concentrations of
DCA included in the agar. The increase in colony yield
was significant with all three concentrations of DCA in
the agar. Data from Stauber et al. (119).
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Figure 5. Effect of DCA on replication rates in normal hepatocytes and c-Jun+ and c-Jun- cells within altered hepatic
foci and tumors. Experiment involved treatment of male B6C3F1 mice for 38 weeks with 2 g DCA/L. At thattime, ani-
mals were transferred to treatments coinciding with the concentrations identified on the x-axis for an additional two
weeks. Cell replication rates were measured by measuring the number of cells that incorporated BrdU into their
nuclei over a 3-day time interval. Replication rates in control animals, or in lesions in mice transferred to 0 g/L for 2
weeks prior to sacrifice are depicted by the solid lines, with the SEM marked by the dashed lines in both cases. Data
from Stauber and Bull (117).
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lure 7. Effect of in vivotreatment of male B6C3F,
mice with 0.5 g DCA/L of drinking water for 14 days on
colony formation of hepatocyte suspensions plated on
soft agar. Dose-response curves were constructed by
subtracting out spontaneously growing colony counts
from those obtained in the indicated concentration of
DCA. Colony counts were made after 10 days in culture.
Data points significantly different from colonies devel-
oped in control incubations are marked with an asterisk
(*). Data from Stauber etal. (119).
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were modeled to determine if the small
lesion size distribution found in previous
studies (117) could be accounted for by the
effects of DCA on tumor growth. The
growth data and prior measurements ofthe
effects of DCA on replication rates within
tumors (117), assuming a suppression of
apoptosis in this cell population was ofthe
same magnitude noted in normal hepato-
cytes ofDCA-treated mice (137), accounted
for the lesion size distribution.
Cytotoxicity and reparative hyperplasia.
Early reports (120) indicated that high doses
of DCA produced localized lesions in the
liver. These lesions led to localized increases
in the labeling index. Subsequent pathologi-
cal analysis ofslides identified the lesions as
acinar necrosis (139). More recently,
DeAngelo and co-workers (76) developed a
dose-response characterization ofthe severity
ofthese lesions. A curve derived from these
data is provided in Figure 9. Necrosis never
involved large portions ofthe liver as indi-
cated by the relatively low scores, and was
confined to treatment levels > 1 g/L. No dif-
ference from control animals was observed at
doses of0.5 g/L. A liver tumor incidence of
approximately 80% is observed at this treat-
ment level (76,117). While these effects may
contribute to the tumor response observed at
high doses, they cannot be invoked as being
responsible for the tumor responses seen at
lowdoses.
Hepatomegaly/cytomegaly. Bull et al.
(73) examined the effects of DCA on the
liver ofB6C3F1 mice in some detail, with
exposure lasting up to 1 year. As had been
alluded to in earlier studies, DCA was found
to produce a severe hepatomegaly in mice at
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Figure 8. Effect of suspending DCA treatment on tumor
growth rates. This experiment involved treatment ofmice
with 2 g/L of DCA until small tumors of approximately 1
mm diameter were detected with magnetic resonance
imaging. Half the tumor-bearing animals were placed on
distilled water, whereas the other half were maintained
on the 2-g/L treatment. Tumors were re-imaged over the
next 2-3 weeks. The growth rates are expressed as a
coefficient of their initial volume. The vertical bars indi-
cate the standard deviation ofthe differences in estimate
of fractional growth, whereas the horizontal bars reflect
the standard deviation of estimates of the differences in
volume measurements. Datafrom Miller etal.(138).
doses at concentrations in drinking water of
1 g/L and above. The hepatomegaly could be
mostly accounted for bylarge increases in cell
size (cytomegaly). Hepatocytes from these
mice stained very heavily for glycogen (PAS)
despite the fact that the livers had been fixed
in formalin. The accumulation ofPAS began
to occur with as little as 1-2 weeks oftreat-
ment (120) but became progressively more
severe with time (73,136). These effects
could not be replicated by exposing mice to
the metabolites ofDCA, glycolate, glyoxylate,
oroxalate, in the drinkingwater (120).
Carter et al. (136) examined the time
course of DCA's effects in the liver of
B6C3Fl mice at concentrations of0.5 and
5 g/L in drinking water. As reported in prior
studies, the high-dose group displayed severe
liver hypertrophy. However, a smaller but
consistent increase in liverweight became evi-
dent with as little as 10 days oftreatment at
0.5 g/L. Even at this relativelylowdose, some
hepatocytes appeared to have lost nuclei or
possess nuclei that had undergone some
degree ofkaryolysis. These experiments also
appeared to rule out cytotoxicity and repara-
tive hyperplasia as a consistent feature of
DCA's effects.
Mather et al. (140) found increases in
liver weight in rats treated with DCA at
5 g/L in their drinking water for 90 days.
Relative liver and kidney weight to body
weight were increased at concentrations of
0.5 g/L and above. PAS staining ofliver sec-
tions revealed accumulation of PAS in
severely swollen hepatocytes that was quite
markedwith 5 g/L DCA.
In contrast, DeAngelo et al. (91) reported
that liver weights were not increased in male
2
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Figure 9. Severity of necrotic damage to the liver in
male B6C3F1 mice treated with various doses of DCAfor
different periods of a lifetime experiment. Note that
such damage varies significantly in time but is only
observed at doses of 1 g DCA/L drinking water and
above. The necrosis involves limited portions ofthe liver
(acinar necrosis). Data are adapted from DeAngelo et al.
(76), but are typical of experiences in other laboratories
(119,120). Each value represents the mean of scores in
the livers of 10 mice ± SEM.
F344 rats chronically administered DCA.
This conclusion is inconsistent with reports
in other strains ofrat. However, the design of
the study may have tended to mask the
hepatomegaly. The high dose ofDCA was
adjusted downward (from 2.6 to 1 g/L) after
18 weeks oftreatment to avoid signs ofovert
toxicity in the rat. The earlier treatment
clearly resulted in substantial losses in body
weight that were apparently not recovered
over the 84 weeks ofthe study. There were
significantly elevated liver-to-body weight
ratios in this group and an increase in both
absolute and relative liver weights at the next
lowest dosing schedule (0.5 g/L), the level
associated with induction ofliver tumors in a
2-yearbioassay (91).
The dog appears to be very sensitive to
the effects of DCA on the liver. Cicmanec
et al. (141) examined the subchronic effects
of DCA in dogs. Dogs were administered
12.5, 39.5, and 72 mglkg/day for 90 days to
groups offive males and five females. Liver
weights were significantly increased in a dose-
related manner beginning with the lowest
dose. By comparison, the lowest effect level
noted in mice is at 0.5 g/L ofdrinkingwater,
which approximates 70-100 mg/kg per day,
while the lowest effect level appears to be 125
mg/kg in rats (122). Thus, the hepatomegaly
induced by DCA is consistently observed
across species.
ComparingtheTumorsInduced
byDCAandTCA
Hyperplastic nodules and tumors induced by
DCA have some characteristics that distin-
guish them from nodules and tumors that are
induced by TCA. Pereira (74) indicated that
in female mice both hepatocellular adenomas
and carcinomas induced by DCA tended to
be eosinophilic, whereas those induced by
TCA were basophilic. In male B6C3F1 mice
treated with 2 g DCA/L, a substantial frac-
tion (66%) ofthe AHF and nodules were
reported to be eosinophilic (117). However,
the larger lesions tend to be basophilic. These
larger lesions included hyperplastic nodules,
adenomas, and carcinomas. These data sug-
gest that there are some differences in tumor
induction by DCA based on sex. However,
this difference appears to be important pri-
marily at high doses (2 2 g/L) where the rate
of cell replication is enhanced in a set of
basophilic lesions. The development ofthese
lesions may account for the much shorter
latencies observed in male vs female mice at
high doses (73).
As pointed out by previous investigators
examining responses in male mice (73,75),
Pereira et al. (74) found that the slope ofthe
dose-response curves describing the induc-
tion oftotal lesions by DCA increases dispro-
portionatelywith dose in female mice. Avery
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similar nonlinear relationship was observed
in the initiation-promotion study (113).
Conversely, the carcinogenic responses to
TCA are essentially linear with dose in both
types ofstudies. In part, the nonlinear char-
acter of the DCA dose-response area is a
function ofauto-inhibition ofits metabolism
as dose increases (47,142).
Stauber and Bull (117) found that DCA-
induced liver tumors in male B6C3F, mice
were immunoreactive to c-Jun and c-Fosanti-
bodies, whereas TCA-induced liver tumors
were not. It was found that this difference in
phenotype could be duplicated bystimulating
the growth ofcolonies from mouse hepato-
cytes suspensions on soft agar in the presence
ofthe two compounds in vitro (119).
Latendresse and Pereira (143) also noted
a number ofdifferences in the phenotype of
tumors promoted by TCA and DCA in the
livers offemale B6C3F, mice initiated with
N-methyl-N-nitrosourea. These authors
found that the majority oflesions promoted
by DCA stained positively for TGF-a and
glutathione S-transferase pi (GSTn). These
markers were not observed in TCA-promoted
lesions. Most interesting was the finding that
DCA-promoted tumors expressed two
cytochrome P450s not observed in the TCA-
promoted tumors, CYP2E1 and CYP4A1.
CYP2E1 is very important to the initial
metabolism ofTCE, particularly at low doses
(7), indicating that metabolites would be
produced in the target cell. This may be of
particular importance to DCA-induced
tumors.
In passing, it should be noted that the
consistency of c-Jun expression noted in
DCA-promoted liver tumors in MNU-
initiated mice (143) was much lower than
previously reported in tumors induced in
male mice (117). This could be a sex differ-
ence, but it is important to recognize that dif-
ferent antibodies were used in these two
studies. Antibodies to c-Jun typically have
been raised against different phosphorylation
sites in the DNA binding or transactivation
regions of the c-Jun protein. These sites are
likely to be differentially affected by c-Jun
activation and, as a consequence, not too
much emphasis should be placed on these
experimental inconsistencies until there has
been some resolution ofthis problem.
DCA- and TCA-promoted tumors differ
in other ways. Tao and co-workers (144)
report that cytosine methylation was
depressed in normal liver and hepatic
tumors initiated by MNU during promotion
with either chemical. Cessation oftreatment
with DCA resulted in a return of cytosine
methylation in adenomas to those found in
noninvolved liver and that of control ani-
mals. This response was not reversed when
TCA treatment was discontinued.
The easiest explanation for these differences
is that DCA and TCA selectively modify the
growth rates ofdifferent clones ofcells that are
present in the mouse liver. It was shown that
treatment ofnormal hepatocytes by the two
compounds had no effect on these pheno-
types. It is difficult to explain such consistent
differences on the basis ofa genotoxic mode
ofaction. These differences are much more
easily explained by suggesting that the two
chemicals interact with differing cell signal
pathways in liver cells that already possess a
modified genotype that renders them more
sensitive to one compound or theother.
Probability That TCE
Is Hepatocarcinogenic
in Humans
The assessment ofwhether TCE poses a risk
ofliver cancer to humans first requires con-
sideration of the available epidemiological
literature. To the extent that epidemiologi-
cal data are less than conclusive, the analysis
must focus on the available data in experi-
mental animals. To extrapolate with confi-
dence, it is necessary to understand how the
tumors are produced in the sensitive species
and whether humans share a similar sensitiv-
ity. It is apparent from considerations above
that both TCA and DCA have properties
associated with tumor promotion. However,
there are distinct differences in the types of
lesions that they induce. One metabolite
(TCA) appears capable of inducing tumors
in only a single species, whereas the other
(DCA) produces tumors in both rats and
mice. The early effects of DCA on the liver
of the dog suggest that this species may be
even more sensitive to low-dose effects of
this metabolite. Therefore, some further
understanding ofthe mechanisms by which
TCA and DCA act is necessary if TCE's
potential to induce liver cancer in humans is
to be determined with certainty. At this
stage, deciding whether humans are sensitive
is not based on strict comparisons of data
generated in human versus test animal sys-
tems (in vivo or in vitro). Thus, at best a
series of testable hypotheses (discussed
below) can be suggested. Essentially, these
reduce to the development of appropriate
pharmacodynamic parameters that can be
applied to measuring the relative intrinsic
sensitivity ofhuman livers in in vitro. Then
pharmacokinetic models can be applied to
account for kinetic and metabolic similari-
ties and differences between species and
across dose ranges. This would allow the
probability that humans are at risk from
TCE to be more precisely defined.
Simplistically, determination ofthe mode
by which TCE induces liver tumors in mice
must first consider: a) the effects that have
been correlated with tumorigenesis by TCE,
b) the extent to which these effects are
accounted for by particular metabolites, and
c) what levels of the particular metabolite
must be achieved within the liver to produce
their effects. A key finding that can be
exploited is the fact that hepatic tumors
induced by DCA can be distinguished from
those induced by TCA; this can then be
extended to identifying which ofthese charac-
teristics are found in tumors induced byTCE.
Effect ofTCEAssociatedwithLiver
TumorInduction
For the purposes of this review, it may be
concluded that there is no evidence that
clearly associates a genotoxic effect ofTCE or
its hepatocarcinogenic metabolites with the
induction of liver cancer. Essentially, this
conclusion is based upon the weak mutagenic
activity ofthe metabolites relative to the con-
centrations that are produced in the metabo-
lism ofTCE in vivo and evidence that other
mechanisms are operative at these systemic
concentrations.
Among the metabolites ofTCE that are
capable of inducing liver tumors, only CH
has produced consistent genotoxic effects.
These have been clastogenic rather than point
mutations. The likelihood that CH con-
tributes as a genotoxin to the carcinogenic
effects ofTCE appears remote. The rapid
metabolism ofthis compound limits its con-
centrations to almost nonmeasurable levels,
even in mice. Mice inhaling 600 ppm TCE
have blood levels of 1.22 pg/ml (145),
whereas approximately 150 pg CH/ml are
observed with intravenous doses of 100
mg/kg ofCH (146). While not directly com-
parable, these data suggest that there is awide
disparity in blood levels ofCH when TCE is
administered than when CH is administered
directly. As a consequence, it seems more
probable that the metabolites DCA and/or
TCA are responsible for the carcinogenic
effects ofTCE.
Elcombe et al. (67) demonstrated that
administration ofTCE in a manner similar to
that used in cancer bioassays of mice was
capable ofproducing a sustained level ofper-
oxisome proliferation. TCA is formed in suf-
ficient concentrations to account for this
response. It must also be concluded that TCA
is making a significant contribution to the
responses to TCE under the conditions ofits
cancer bioassays. Thus, TCA is probably
making a substantive contribution to the
induction ofliver tumors in mice chronically
treated with TCE. TCA also induced peroxi-
some proliferation in rats. However, neither
TCA norTCE induces liver tumors in rats.
Cytotoxicity and reparative hyperplasia
are not prominent features ofdoses ofTCE
that are sufficient to induce cancer. At least
with short-term treatment, TCE and two of
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its metabolites modify cell replication and
death rates. Increases in cell replication early
in the course oftreatment have been noted
for TCE and appear to reflect a mitogenic
effect (67,68). Stimulatory effects have also
been reported for DCA at 2 and 2.6 g/L and
TCA at concentrations in drinking water of
0.32-3.2 g/L (117,121). Almost all investi-
gators have observed a depression ofhepato-
cyte replication with continued treatment
with both compounds (121,137).
It is remarkable how well the effects of
DCA and TCA on cell division conform with
their respective dose-response curves for
cancer induction. The nonlinear relationships
with dose in DCA-induced liver tumori-
genesis, whetherobservedwhen bioassayed as a
complete carcinogen (73,74) or as a promoter
in an initiation-promotion study (113), are
consistent with the differential inhibition of
normal cell replication at low doses and the
marked stimulation of replication within
tumors at high doses (117). Conversely, the
apparent linear dose-response curve with
TCA-induced cancer under similar circum-
stances (73,74,113) is consistent with the fact
that only thedifferential suppression ofnormal
cell replication was observed (117). While the
mechanisms ofaction ofthese two chemicals
appear to be distinct, these data suggest that
both are actingprimarily through modification
ofcell birth and death processes.
Theprincipal difference in the mechanisms
ofDCAand TCAappears to be related to the
cell populations to which they provide a
selective advantage. The tumors induced by
TCA appear to have an innately greater rate
ofreplication than those induced by DCA. In
other words, TCA appears to be selecting ini-
tiated cells that are more aggressive than those
selected by DCA at low doses. However, at
higher doses the strong and selective mito-
genic effect ofDCA on tumor cells increases
the growth rate oftumors with a less malig-
nant phenotype (114). This stimulus to the
growth rate is what appears to account for the
very nonlinear dose-response relationship for
tumorigenesis induced by DCA. The very
large increase in tumor multiplicity in mice
treated with DCA when doses are only
increased by a factor of 2 in the high dose
range that has been noted by all investigators
reinforces this interpretation.
The extent to which replication rates in
normal hepatocytes are decreased with longer
term treatments withTCE has not been inves-
tigated. In itself, this possibilitywould not dif-
ferentiate between the mechanisms postulated
for DCA and TCA. A more diagnostic deter-
mination would be whether the tumors
induced by TCE are sensitive to stimulation
ofcell replication rates by DCA. A second dif-
ference is the distinctly different phenotypes
with respect to c-Junimmunoreactivity.
The inevitable confounding ofrates ofcell
replication with rates ofcell death makes it
difficult to determine ifthe effects are exerted
on one process or the other. The rate ofcell
replication must equal the cell death rate at
steady state in normal tissue. The question of
whether depressed cell replication rates within
initiated cell populations result from down-
regulation in response to a chronic mitogenic
effect or by a more specific interference with
apoptosis can have substantively different
implications for risk assessment. Depressed
apoptosis could imply interference with the
death ofa cell in which damage to DNA has
been recognized by the cell. The replication
ofsuch cells could be an efficient means of
producing initiated cells. Until such time that
these cells progress to more stable lesions,
they should be very sensitive to apoptosis if
treatment is suspended. However, ifcells are
selected that have a higher probability for
progression to tumor, then rapid induction of
a malignant phenotype might be observed.
Conversely, a simple downregulation ofmito-
genesis may be a more benign process. Such
differences may underlie the apparently less
aggressive properties ofDCA-induced tumors
rather than TCA-induced tumors (73,114).
While the mechanisms underlying these
modifications ofcell division anddeath are not
yet known, these findings frame a mode of
action forTCE-inducedlivercancer that is not
dependent upon chemically induced mutation.
Howare these findings to be translated into an
assessment ofpotential human risks to liver
cancer induced by TCE? Most critical to the
low-dose extrapolation is whether small distur-
bances in cellular control mechanisms have
pathological consequences. IfDCA- andTCA-
induced mechanisms can be assumed to be
good models for TCE-induced carcinogenesis,
it would appear that tumors are only induced
by doses ofthe compounds that result in sig-
nificant downregulation ofnormal control
mechanisms in normal cells. Apparently it is
this negative selection process that is active at
lowdoses ofboth metabolites. Ifsufficient per-
turbation has to be produced in normal cells
for downregulation to be observed, then it is
probable that the tumorigenic response has an
effective threshold.
DCA and TCA both produce hepato-
megaly in the dose ranges in which they
induce hepatic cancer. In part, these
changes reflect the initial effects of both
chemicals on increasing cell replication
rates. However, some of the effects of both
compounds, but most particularly DCA in
mice, are the results of cytomegaly.
Empirically, it might be useful to consider
TCE's effects on liver weight as an early
measure ofprocesses that may be involved
in liver cancer induction. The substantive
differences in the character of the liver
enlargement that is induced by the two
metabolites indicate that care must be taken
not to carry this parallel too far.
It is clear from this analysis that there is
altered control ofcell replication in TCE-
treated mice. These effects have been demon-
strated by administering either TCE directly
or one oftwo metabolites thought responsible
for its induction ofliver tumors in mice.
Mutation spectra in codon 61 ofthe H-ras
protooncogene are consistent with a role of
DCA in TCE-induced liver cancer. It is
unlikely that these mutations play a signifi-
cant role in the initiation ofthe tumorigenic
response to either TCE or DCA because
these mutations are generally less abundant
than the wild-type form ofthe gene in most
tumors and therefore would not be an early
event in the process (42,45).
EffectiveLevels ofTCEMetabolites
Fisher (70) has provided a review of the
pharmacokinetics ofTCE and its metabo-
lites. It is necessary, however, to touch on
this issue briefly to support any conclusions
that a particular metabolite can be held com-
pletely or partially responsible for liver tumor
induction.
TCA is the metabolite that circulates in
the blood at the highest concentration in all
species, including humans (81,83,145,146).
Under conditions ofthe bioassays forTCE, it
appears that there is evidence ofperoxisome
proliferation in mice (67). Blood concentra-
tions ofTCA following administration of
doses of TCE used in the NCI and NTP
studies are in the same range required for
activation ofthe PPARa (147). Thus, TCA
can account for these observations withTCE.
The other hepatocarcinogenic metabolite
is DCA, which could arise through several
pathways (54,148-150). Recent data indicate
that at carcinogenic doses ofTCE, DCA in
blood can be barely detected but not quaniti-
fied, and then only after its metabolism was
inhibited by prior treatment (48). Thus, an
upper limit of1-2 pM (130-260 ng/mL) can
be estimated as a maximum concentration of
DCAfollowing a 1-g/kg dose ofTCE admin-
istered by gavage. A more probable concen-
tration would be about an order of
magnitude lower based on the clearance ofa
20-mg/kg dose ofDCA from the blood of
naive B6C3Fi mice (48). In contrast, con-
centrations ofDCA in blood ofmice chroni-
cally treated with 2 g DCA/L were found to
be 300 pM (39 pg/ml) during the period
when they were actively drinking water (5
AM.), but fall to 10% ofthis level 4 hr later
(9 A.M.). Concentrations observed with DCA
treatment at 0.5 g/L were found to be
approximately 2-4 pM (250-500 ng/mL)
during the night (47), but these concentra-
tions fell rapidly to levels below the limit of
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quantitation by9 A.M. Thus, the concentrations
of DCA in the blood of mice treated with
1,000 mg/kg TCE (2 gM) may be within
range ofa concentration that appears effec-
tive in producing liver cancer in mice treated
with 0.5 g/L DCA directly. These concentra-
tions are within an order of magnitude of
those that produced clonal expansion ofcells
sensitive to DCA in vitro (20 ,uM) (119).
Other more complex mechanisms may be
active in the intact animal, possibly an indi-
rect mechanism that stems from differential
accumulation ofglycogen in normal liver
cells and liver tumor cells (73). This type of
mechanism would require interactions
between the initiated cells and adaptation of
serum hormone levels to effects produced in
normal hepatocytes. Modeling such complex
responses has not been attempted in an in
vitro system. The complex differences that
result from differing modes of DCA and
TCE administration make further compar-
isons difficult without additional data.
However, TCE still may be metabolized to
DCA in quantities that it could contribute to
the carcinogenic response.
DCA is unlikely to contribute to the
induction ofperoxisome synthesis at levels
that are produced by the metabolism ofTCE.
Maloney and Waxman (147) found that
concentrations in the range of0.5-1 mM are
necessary to activate the PPARa. These con-
centrations are about three orders ofmagni-
tude higher than would be produced from
the metabolism ofTCE and the concentra-
tions of DCA that result from the direct
administration of DCA at doses that are
dearly carcinogenic in the mouse.
A direct role for CH in the induction of
liver tumors is difficult to establish because it
is largely converted to TCA in vivo (146). A
possibility ofit making an independent con-
tribution to hepatocarcinogenicity ofTCE is
ofconcern because, as discussed above, this
metabolite appears to be clastogenic. The
vanishingly small concentrations ofCH that
would be anticipated from environmental
exposures to TCE relative to those that arise
from carcinogenic doses of CH that is
directly administered, however, make this
contribution unlikely.
Since TCE, CH, and TCA do not induce
liver tumors in rats, it is difficult to support
the hypothesis that they represent a trans-
species risk for this tumor site. Only DCA
would appear to have the capability ofinduc-
ing liver cancer in multiple species. Recent
data suggest that DCA's contribution to the
induction ofliver cancer in humans by low
doses ofTCE would be negligible. That is
because ofthe lower formation DCA antici-
pated in humans relative to mice and the
probability that it will have a sublinear
toxicodynamic profile.
ImplicationsforAssessment
of Risks at Low Doses
The available data suggest that the induction
ofliver tumors byTCE results from a modifi-
cation ofcell-signaling systems that control
rates ofcell division and death. Unlike chemi-
cals that induce mutation, such mechanisms
have only been recently dealt with in models
for low-dose extrapolation. In no case have
the risks for such chemicals been explicitly
dealtwith in the regulatory arena.
In the case ofTCE, the issue is compli-
cated by several factors: a) It is probable that
more than one cell-signaling system is being
modified, at least one by TCA and another
by DCA. b) The details of these pathways
are not completely known, and it will be dif-
ficult, based upon currently available data,
to predict how simultaneous modification of
these pathways might alter the outcome. c)
It is not possible to describe their control
functions in detail and in quantitative terms.
d) Although critical components of both
pathways are found in most mammalian
species, there are clearly differences in the
amount of receptor present and the overall
mechanisms of regulation in different
species with at least one of these pathways
(i.e., PPARa-dependent signaling).
Cell signaling falls into two general
types: Those linked to receptor proteins that
are embedded in the cell membrane (e.g.,
epidermal growth factor, insulinlike growth
factors) and those that are intracellular
receptors (e.g., estrogen receptors, PPARs)
(151). The pathways coupled to membrane
receptors typically involve a cascade of
protein-protein interactions that involve
cycles ofphosphorylation/dephosphorylation
of key intermediate signaling proteins.
There are often several different phosphory-
lation sites on these proteins and the func-
tional state of the protein can be modified
independently and in opposite directions by
phosphorylation at different sites. The
nuclear receptors generally fall into a cate-
gory of ligand-activated transcription fac-
tors. Control of the transcription of
particular proteins can be modified through
formation of a variety of heterodimers that
facilitate or inhibit the transcriptional acti-
vation of the complex. Frequently, the
activity of these factors can be modified by
phosphorylation/dephosphorylation cycles.
Both membrane receptor and intracellular
receptor signaling pathways have complex
functions. Frequently, similar functional
activities can be influenced by both types of
pathways and by a variety ofpathways within
each group. For example, apoptosis can be
initiated by stimulation ofT-cell, FaslApol,
steroid, TGF-P, or tumor necrosis factor
receptors (152). Both types ofcell-signaling
systems are activated or inhibited by a wide
variety ofphysiological variables, as well as
being modified by chemicals that produce
cancer. Both are known to influence rates of
cell division and death. Moreover, they mod-
ify one another's activities in this respect. A
second example is that insulin induces phos-
phorylation ofthe PPARa and increases its
transcriptional activity (153). At present, the
unknowns involved in each type ofcontrol
mechanism are too many to incorporate for-
mally into models for low-dose extrapolation.
Therefore, it is important to develop more
general conceptualizations of how such
modes ofaction are likely to contribute to
carcinogenic responses at lowdoses.
As a result ofour limited knowledge, it is
easier to analyze how perturbations in these
control systems manifest themselves in
processes known to affect the course of car-
cinogenesis. Carcinogenic effects would result
from achemical's ability to activate apathway
that increases cell replication or to inhibit a
pathway that activates apoptosis. Apoptosis
and cell replication are not independent vari-
ables and, in part, make use of some ofthe
same signaling pathways (154). In mature
organisms, cell birth and cell death rates are
equivalent under normal circumstances. A
carcinogen that acts by modifying these
processes can do so by providing a clone of
initiated cells a growth advantage relative to
normal cells (154,155). There are implica-
tions for low-dose extrapolation that relate to
a more rapid rate at which cells are turning
over within a tissue, as this appears to lead to
increased mutation rates (156).
In general, ifthe primary molecular inter-
action ofa chemical is with a protein involved
in cell signaling, the impact at low doses may
differ depending upon where signal transduc-
tion within the pathway is modified.
Typically, these systems amplifysignals, so the
impact ofinterference with a receptor mole-
cule at the cell membrane or at thelevel ofthe
regulated transcription factor may have differ-
ing dynamics than interference with some
intermediate step in a signaling cascade. The
implications for low-dose extrapolation may
also differdepending uponwhether the chem-
ical is directly affecting the critical pathway or
is the result ofcross-talk from parallel path-
ways with another set ofregulatory functions.
In addition, all such pathways are subject to
downregulation by one means or another. A
strong, sustained downregulation means that
the normal cells have lost the effective control
provided by that signaling pathway. The cell
then must depend on other systems to control
the primary functions ofthe downregulated
pathway. Inevitably this leads to some imbal-
ances that may produce other disturbances in
homeostatic mechanisms that range from
basic control ofintermediary metabolism to
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higher level organ-specific functions. This
becomes analogous to mutation, where initi-
ated cells can no longer make effective use ofa
pathwaycontrolling cell replication ordeath.
To a point, the dynamics of a cell-
signaling pathway are based on the classical
continuous or graded dose-response curves
that are familiar to pharmacologists. At some
stage the activation or inhibition ofsuch a
pathway results in a stochastic response, i.e.,
an additional cell division or prevention of
the death ofa single cell. In other areas of
biology, this behavior is viewed as a thresh-
old. Are there thresholds that limit the impact
ofminor perturbations in the cell-signaling
systems that control birth and death rates of
cells? This question has received little experi-
mental attention in carcinogenesis.
Another critical question is reversibility.
It is reasonably clear that within the physio-
logical range, modification ofcell-signaling
pathways by chemicals should be reversible,
either through dissociation ofthe chemical
or by biosynthetic replacement of an irre-
versibly damaged protein. Even stochastic
responses such as cell replication can be
reversed by early apoptosis. As these
responses become sustained, however, some
irreversible pathological events (such as
immortalization) may be triggered. In the
case ofincreased cell replication, it has been
held that each cell division carries with it a
probability of error in DNA replication
(156). The destiny ofthese mutated cells is
known to depend on a number offactors too
numerous to deal with here. However, it is
clear from animal studies that while many
cells become initiated, the probability that
theywill grow and progress to tumor is small
(157). Conversely, we know from human
experience that such rare events underlie the
development ofcancer (158). The question
is whether mutation rate is really the rate-
limiting process. Survival and replication of
initiated cells may actually be more impor-
tantwith some environmental carcinogens.
In a similar fashion, the impact of
suppressed apoptosis may be short-lived if
exposure is intermittent. What is the fate ofa
stem cell whose death has been temporarily
postponed? Are such cells likely to die when
the chemical exposure is intermittent or is
terminated? Evidence for such a fate seems to
be coming from stop experiments, in which
tumors are observed to regress after removal
ofthe chemical treatment. Regressions ofthis
type are well established in cancer resulting
from initiation-promotion studies in the skin
(159), and there are recent examples ofsuch
behavior in liver tumor induction as well
(160). It is difficult to envision a linear
dose-response curve at low doses if the
response remains reversible at such a late stage
in tumorigenesis.
As stated earlier, there must be some
differential effect ofa chemical on normal cells
and initiated cells for it to be an effective pro-
moter ofcancer. It is probable that such differ-
ential sensitivity will arise from a lessor ability
ofthe initiated cell to downregulate the system
responding to the chemical treatment. To
some extent this appears to be characteristic of
both DCAandTCA, despite the fact that they
tend tostimulategrowthoftumorswith differ-
ent characteristics. From the work ofStauber
and Bull (117), the initial stimulation ofcell
replication within the normal cell population
appears to be followed not only by a loss of
sensitivity to the mitogenic effects ofthe com-
pound but also by an actual inhibition ofcell
replication. In neither case was the rate of
replication among initiated cells so reduced. In
the case ofDCA, the initiated cells contained
within nodules ortumors appear to retain their
sensitivity to the mitogenic effects ofhigher
doses, but the downregulation ofnormal cell
replication appeared to be the predominant
effect at lower doses. This general mode of
action has been associated with other tumor
promoters such as phenobarbital (118). Acrit-
ical question that arisesfrom this observation is
whether there is any increased risk for cancer
from chemicals that act thiswayatdoses below
those that result in downregulation of the
mitogenic response. Ifincreased risk could be
established, then there would be a clear basis
for considering threshold exposure levels for
tumor-promoting agents. Ifthis can be shown,
the next question is how to experimentally
identifythedoses atwhich this occurs.
For experimentalists, the critical question
is whether the probability ofa tumorigenic
response can be quantitatively associated with
a transition between a physiologically respon-
sive pathway, one that has been down-
regulated to the point that it is no longer
responsive to normal variations in physiologi-
cal conditions. There is a concordance in the
dosing schedules ofDCA and TCA that pro-
duce downregulation ofa mitogenic effect of
the chemicals on normal cells and those that
produce hepatic tumors in mice (71,113,
117,137). While this dosing level with DCA
produces > 80% incidence oftumors in mice
over alifetime, there is no evidence ofcarcino-
genic response at dosing levels one order of
magnitude lower (71,76). To the extent these
two metabolites can account quantitatively
and qualitatively for liver tumors induced by
TCE in mice, the risk for liver cancer should
approach zero at doses ofTCE that do not
generate sufficient amounts ofthese metabo-
lites to induce these responses.
A number ofexpert panels (1,52) have
reviewed the risk assessment issues with per-
oxisome proliferators and have concluded
that there is insufficient basis for concluding
that these compounds do not represent a
carcinogenic hazard to humans. However,
both panels have generally concluded that
peroxisome proliferators, per se, are unlikely
to represent a carcinogenic hazard under
anticipated conditions and levels ofexposure,
but their carcinogenic potential cannot be
ruled out under any conditions ofexposure.
Cattley et al. (52) suggested that a case-by-
case assessment using a margin-of-exposure
approach would be most appropriate for
attempting to provide quantitative estimates
of risk. The panel also concluded that all
available data be considered, in part because
an ability to act as a peroxisome proliferator
does not exdude the possibilityofother prop-
erties that could independently contribute to
the development ofcancer.
Research Questions Remaining
When changes occur in the guidelines for risk
assessment such as those recently proposed by
U.S. EPA (4) that allow mechanistic data to
substantively impact the weight-of-evidence
and quantitative evaluations, questions arise as
to the condusive nature ofthe data. It will be
a rare circumstance, at least in the foreseeable
future, ifthe mode ofaction ofmany carcino-
gens is fully described with confidence. The
question is really defining when the available
data are sufficient for moving beyond the
default positions in a riskassessment. Research
to further clarify the issue could go on end-
lessly. Ifthat appears to be necessary, however,
one must seriously question the role that new
science should have in the decision-making
process. The following listing ofresearch areas
relative to clarifying the mode of action of
TCE (and its metabolites) in the induction of
liver cancer represents a finite series ofques-
tions that would appear more-or-less critical
to near-term decision-making. However, the
list is not meant to suggest that all research is
absolutelyessential before a change in riskpol-
icyforTCE can be made.
ClarificationoftheRoleofMetabolites
intheHepaoatrcinogenicEffcts
ofTCE
Defining the nature ofinteractions between
CH, DCA, and TCA in liver tumor induc-
tion in mice would aid in a better under-
standing ofhow the tumorigenic activity of
TCE should be extrapolated to low dose. To
be useful, these studies would have to be
quantitative to ensure that the concentra-
tions produced in vivo are realistic with
respect to the expected concentrations seen
within the liver.
Relevance oftheMechanisms Involved
inHepatic Carcinogenesis ofTCE
to Humans
The result ofactivating the PPARs in human
systems is becomingdearer, but the connection
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of those responses to the tumorigenic
responses in rodents requires further delin-
eation. At present, data with regard to TCA
identify it as aperoxisome proliferator, but this
evidence is correlative and far from definitive.
Experiments with PPARa-Knockout mice
couldprovidemoredefinitive evidence.
In the case ofDCA, understanding the
effects ofchronic TCE-treatment on serum
insulin levels and normal hepatocyte and liver
tumor cell levels ofinsulin receptor expres-
sion would be useful in determining the
extent to which DCA plays a role in the
induction ofliver tumors. Clearer delineation
ofperturbations induced by either metabo-
lite in cell-signaling pathways will allow the
direct measures ofhuman responses to be
evaluated. These biomarkers ofeffect could
greatly facilitate evaluation of whether
humans are at significant risk ofliver cancer
from TCE and several other related solvents.
In the case ofboth TCAand DCA, there is a
clear path for comparing human and rodent
sensitivities to these metabolites of TCE
using the in vitro clonal expansion system
described byStauber et al. (117).
BehavioroftheMechanismsofIver
TumorInduction atLowDoses
One must continually keep in mind that
evidence oftumorigenic response to TCE and
its metabolites has been obtained only at very
high doses. Virtually all ofthe concern that is
generated about the low levels ofTCE that
are encountered in the general environment
come from the application ofalinearextrapo-
lation model to what appear to be strain-
specific responses obtained at these very high
doses. The use of the linear model for
dose-response modeling is based upon
assumptions about a genotoxic mode of
action ofTCE and its metabolites in the
induction ofliver cancer. Data have emerged
that indicate that this assumption does not
apply. Evidence is growing that DCA and
TCAact primarily bymodifying cell-signaling
systems. Since the activity ofcell-signalingsys-
tems is constantly modified as part ofnormal
physiological function, it seems unlikely that
perturbations that do not take them outside
their normal operatinglimits aregoing to have
irreversible and cumulative effects. This
hypothesis is testable using variations in the
clonal expansion system used by Stauber et al.
(117) and by in vivo experiments that more
precisely pursue the effects ofTCE's metabo-
lites on rates ofcell division and cell death
within initiated cell populations atlowdoses.
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